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ABSTRACT
THE ROLE OF SUGAR-SWEETENED BEVERAGES AND VITAMIN D
IN ELEVATED SYSTOLIC BLOOD PRESSURE
SEPTEMBER 2017
AMANDA HAUTANIEMI ABRAMS, B.A., MOUNT HOLYOKE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Alayne G. Ronnenberg
High sugar-sweetened beverage (SSB) intake and poor vitamin D status have both been
associated with increased risk of elevated systolic blood pressure (SBP) in previous research.
However, these associations have never been investigated in the same study population, leaving
the question of a possible interaction uninvestigated. One potential mechanism for an
interaction is that SSB intake may increase serum uric acid (UA) and UA may interfere with
utilization of vitamin D. This study examined these relationships in a sample of men and women
(n=2,875) aged 20-74 using data collected in the 2003-2006 NHANES survey. No statistically
significant association was found between SSB intake and risk of elevated SBP (defined as
SBP>120mmHg) in whole group analysis. In subgroup analysis by gender, women (n=1,550)
showed a 68% (OR: 1.68, 95% CI: 1.12-2.50, p-value 0.011) increased risk of elevated SBP in the
highest SSB intake quartile (mean intake of 3.27 servings/day) compared to the lowest (mean
intake of 0.03 servings/day) after adjustment for age, race, BMI, alcohol use, physical activity,
and smoking, but no association was found in men (n=1,325). A statistically significant
association was found between 25(OH)D and SBP, with a 30% decrease in risk of elevated SBP
(OR: 0.70, 95% CI: 0.55-0.90, p-value 0.005) for those in the highest serum 25(OH)D group
(>75nmol/L) compared to the lowest (<50nmol/L) in the fully adjusted model. However, no
association was found between SSB intake and serum UA. Assessing potential effect
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modification between SSB and vitamin D in their impact on blood pressure using a multiplicative
term and stratified analysis did not provided evidence of an interaction effect.

iv

TABLE OF CONTENTS
Page
ABSTRACT........................................................................................................................................ iii
LIST OF TABLES ................................................................................................................................vii
LIST OF FIGURES .............................................................................................................................viii
CHAPTER
1. INTRODUCTION ............................................................................................................................ 1
2. LITERATURE REVIEW .................................................................................................................... 4
2.1 Blood Pressure Regulation .................................................................................................... 4
2.1.1 Renin-Angiotensin-Aldosterone System (RAAS) ............................................................. 4
2.1.2 Pressure Natriuresis (PN) ................................................................................................ 5
2.2 Sugar-Sweetened Beverages and Blood Pressure ................................................................ 7
2.3 Sugar-Sweetened Beverages and Uric Acid ........................................................................ 15
2.4 Vitamin D and Uric Acid ...................................................................................................... 20
2.4.1 25-hydroxyvitamin D..................................................................................................... 21
2.4.2 1,25-Dihydroxyvitamin D and 1-α hydroxylase ............................................................ 25
2.4.3 Parathyroid Hormone (PTH) ......................................................................................... 27
2.5 Discussion............................................................................................................................. 30
3. HYPOTHESIS AND SPECIFIC AIMS ............................................................................................... 34
4. METHODS ................................................................................................................................... 35
4.1 Study Population .................................................................................................................. 35
4.2 Measurements ..................................................................................................................... 36
4.3 Statistical Analysis ................................................................................................................ 37
5. RESULTS...................................................................................................................................... 39
6. DISCUSSION................................................................................................................................ 48
6.1 Sugar-sweetened Beverages and Hypertension ................................................................. 48
6.2 Vitamin D and Hypertension ................................................................................................ 50
6.3 Interaction Between SSB Intake and Vitamin D ................................................................... 53
6.4 Limitations............................................................................................................................ 54
6.5 Future Directions ................................................................................................................. 54
v

6.6 Conclusion ............................................................................................................................ 55
BIBLIOGRAPHY ............................................................................................................................... 56

vi

LIST OF TABLES

Table

Page

2.1: Observational studies of SSBs and BP in adults ........................................................................ 9
2.2: Observational studies of SSBs and BP in adolescents............................................................. 11
2.3: Assessing effect of change in SSB intake over time... ............................................................. 13
2.4: Observational studies of impact of difference in 25(OH)D on UA.......................................... 22
2.5: RTC and intervention studies of impact of difference in 25(OH)D on UA .............................. 23
2.6: Observational studies of impact of difference in UA on 25(OH)D.......................................... 25
2.7: Animal and cellular studies of impact of UA on 1,25-Dihydroxyvitamin D
and 1-α hydroxylase....................................................................................................................... 27
2.8: Observational studies of association between PTH and UA ................................................... 29
5.1: Subject characteristics by normal versus elevated SBP (n=3,287) ......................................... 40
5.2: Linear and logistic regression analysis of the association of SBP with SSB intake ................. 41
5.3: Linear and logistic regression analysis of the association of SBP with
SSB intake in women...................................................................................................................... 42
5.4: Linear and logistic regression analysis of the association of SBP with Vitamin D .................. 44
5.5: Linear and logistic regression analysis of the association of SBP with PTH (pg/mL) .............. 45
5.6: Linear and logistic regression analysis of the association of SBP with
SSB intake and Vitamin D ............................................................................................................... 47

vii

LIST OF FIGURES

Figure

Page

2.1: Uric acid metabolism. ............................................................................................................. 15
2.2: Difference in UA production in response to SSB intake by gender. ....................................... 19
2.3: Proposed pathway .................................................................................................................. 33

viii

CHAPTER 1
INTRODUCTION

For a disease that affects one in three American adults, hypertension (HTN) is elusive.
Largely asymptomatic, it hides in plain sight while earning the moniker “the silent killer” by
contributing to the death of around 1,000 Americans every day (CDC, 2016). There are two
things that make hypertension so difficult to combat: the underlying cause of primary
hypertension is unknown and only about half of people diagnosed with hypertension are
meeting their blood pressure targets, despite the over 75 drug treatments available (CDC, 2016).
In secondary hypertension, such as obvious injury to the kidneys, hypertension is a symptom of
another disease state and will resolve when the underlying cause is treated. When the
underlying cause is not known, it is called essential or primary hypertension, but the dichotomy
is a false one. The goal of hypertension research is to understand the underlying cause behind
cases that are currently considered essential so that they, too, can be resolved. Myriad subtypes of hypertension may eventually be found within the current umbrella term. Each of these
discoveries will hopefully also move more patients out of the resistant hypertension category, as
understanding the causes will lead to better, more targeted prevention and treatment
strategies.
Poor vitamin D status has been linked to HTN in cross-sectional and cohort studies. A
2011 meta-analysis found that the risk of developing HTN was 27% lower among persons in the
highest verses the lowest category of serum 25-hydroxyvitamin D (Odds Ratio (OR): 0.73, 95%
confidence interval (CI): 0.63–0.84) (Burgaz, 2011). Mechanisms proposed for this protective
effect are that the active form of vitamin D has been shown to reduce renin secretion and
smooth muscle proliferation in vascular tissue (Forman, 2008). However, the story changes with
1

attempts to lower blood pressure (BP) through vitamin D supplementation. Meta-analysis of 46
randomized placebo-controlled clinical trials found no effect of supplementation on BP
(Beveridge, 2015). One possible cause of this unexpected outcome would be if some other
factor were involved in the relationship between vitamin D and hypertension. Without
accounting for this other factor, analysis of change in BP relative to change in vitamin D levels
might reveal no relationship.
A possibility for that missing factor could be sugar-sweetened beverages (SSBs). Many
cross-sectional and cohort studies that examined SSB intake found a positive association
between higher intake and increased blood pressure or the risk of developing hypertension
(HTN) (Barrio-Lopez, 2013; Bremer, 2009; Cohen, 2012; Duffey, 2010; Ejtahed, 2015; Mirmiran,
2015; Nguyen, 2009; Sayon-Orea, 2015; Wang, 2013). A 2015 meta-analysis of 6 cohort studies
found a 12% higher risk of HTN (Risk Ratio 1.12, 95% CI: 1.06-1.17) for highest (≥1 SSB/day)
versus lowest (none) quantile of SSB intake (Jayalath, 2015). Studies that examined the effect of
reducing SSB intake have shown a blood pressure lowering effect or reduced risk of developing
HTN (Chen, 2010; Sayon-Orea, 2015). One mechanism by which SSB intake is thought to raise BP
is through the ability of high fructose intake to induce an increase in serum UA concentration
(Perez-Pozo, 2010; Nakagawa, 2006; Sanchez-Lozada, 2007, Wang, 2012). Mild hyperuricemia
has been shown to induce BP elevation in animal models by increasing renin production and
decreasing nitric oxide production, thereby disrupting endothelial function (Khosla, 2005;
Mazzali, 2001). These mechanisms are suggestively similar to those found for low vitamin D
status.
The purpose of this study was to explore the association between SSB, vitamin D status
and BP and determine whether these factors in combination modify the main associations with
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blood pressure. Could good vitamin D status protect against the impact of high SSB intake on
BP? Or could high SSB intake nullify the positive effect of vitamin D repletion? The possibility
that uric acid is the mediator in that interaction was also investigated. To our knowledge, the
relationship between SSBs, vitamin D and HTN has not been explored previously.
This study examined these relationships in a sample of men and women (n=2,875) aged
20-74 using data collected in the 2003-2006 NHANES survey. No statistically significant
association was found between SSB intake and risk of elevated SBP (defined as SBP>120mmHg)
in whole group analysis. In subgroup analysis by gender, women (n=1,550) showed a 68% (OR:
1.68, 95% CI: 1.12-2.50, p-value 0.011) increased risk of elevated SBP in the highest SSB intake
quartile (mean intake of 3.27 servings/day) compared to the lowest (mean intake of 0.03
servings/day) after adjustment for age, race, BMI, alcohol use, physical activity, and smoking,
but no association was found in men (n=1,325). A statistically significant association was found
between 25(OH)D and SBP, with a 30% decrease in risk of elevated SBP (OR: 0.70, 95% CI: 0.550.90, p-value 0.005) for those in the highest serum 25(OH)D group (>75nmol/L) compared to the
lowest (<50nmol/L) in the fully adjusted model. These findings are generally consistent with
previous research. However, no association was found between SSB intake and serum UA, which
was unexpected, as the possible ability of high SSB intake to increase serum UA has been widely
speculated to be a mechanism by which SSBs might increase BP. Assessing potential effect
modification between SSB and vitamin D in their impact on blood pressure using a multiplicative
term and stratified analysis did not provided evidence of an interaction effect. As the proposed
mechanistic link between SSB intake and vitamin D was UA, finding no interaction effect is
consistent with the finding of no association between SSBs and UA.
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CHAPTER 2
LITURATURE REVIEW

2.1 Blood Pressure Regulation
2.1.1 Renin-Angiotensin-Aldosterone System (RAAS)
The RAAS is the principal means of blood pressure regulation. Blood pressure is
monitored in the kidneys by the macula densa cells of the juxtaglomerular-complex. These cells
are sensitive to the pressure of blood coming through the afferent arteriole of the nephron. If
pressure is too low, macula densa cells release the enzyme renin into the blood stream. Renin
converts angiotensinogen to angiotensin I, which is then converted to angiotensin II by
angiotensin converting enzyme (ACE) found in the lungs. Angiotensin II is a vasoconstrictor, so it
has an immediate effect on blood pressure. It also travels to the adrenal glands and triggers the
release of aldosterone, which then completes the circuit, returning to the kidneys where it acts
on the distal nephron, signaling for an increase in epithelial sodium channels placed into the
apical surface. (Mironova, 2015) Water is then able to travel down its concentration gradient by
osmosis back into the blood stream. The resulting increase in blood volume boosts blood
pressure, returning it to the normal range, which, in turn, signals the macula densa cells to stop
secreting renin and the RAAS is shut down. While this whole-body view of the RAAS is the most
widely accepted model, some argue that all of the steps of the RAAS system can also take place
exclusively in the kidney. They state that small amounts of all of the molecules involved, such as
ACE and aldosterone, are made intrarenally, arguing that this mechanism plays a role in
hypertension. (Wadei, 2012)
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The renin-angiotensin-aldosterone system is a key mechanism for long-term blood
pressure regulation that is very effective at correcting low blood pressure by increasing blood
volume. However, RAAS is a poor way to correct high blood pressure, since the only way it can
act to reduce blood pressure is to turn off. Once RAAS is shut down, new epithelial sodium
channels will stop being placed into the collecting ducts, but the existing ones will continue to
function until they break down. In effect, the signal that blood pressure is too high can only be
acted on at the speed of protein turnover. (Mironova, 2015) This may be surprising, given the
number of anti-hypertensive medications that focus on interrupting RAAS. These drugs are
effective in patients where the homeostatic disregulation that is resulting in hypertension is that
the RAAS is stuck in the “on” position. For some reason, the juxtaglomerular-complex is
continuing to secrete renin, telling the body that blood pressure is too low when it is in fact
above the normal range. Another facet of this mechanism is paracrine signaling in the collecting
duct, with ATP used as the signal molecule, a type of purinergic signaling. This purinergic signal
should block the epithelial sodium channels to prevent sodium reabsorption when blood
pressure is high. Defects in this purinergic signaling system in the kidneys also interfere with
blood pressure regulating effects of pressure natriuresis, discussed below. (Mironova, 2015)

2.1.2 Pressure Natriuresis (PN)
In addition to the RAAS system, blood pressure is controlled by the pressure natriuresis
response, which takes place entirely in the kidneys. When blood pressure rises, it causes an
increase in water and sodium excretion by the kidneys. This in turn lowers fluid volume
throughout the body and returns blood pressure to the normal range. A feature to note about
PN is that it inhibits the renin-angiotensin-aldosterone system. If it is functioning properly,
5

pressure natriuresis is also one way that the body can compensate for an overactive RAAS. This
was demonstrated in a study were dogs were infused with excess aldosterone. The dogs whose
PN system was uninterrupted were able to maintain normal sodium balance in spite of the
excess aldosterone. (Granger, 2002)
Despite tight homeostatic control of renal blood flow and glomerular filtration rate,
renal perfusion pressure increase is associated with increases in renal interstitial hydrostatic
pressure (RHIP). (Granger, 2002; Ivy, 2014) The increase in pressure is thought to be transmitted
into the interstitium via the vasa recta, the blood vessels that run parallel to the loop of Henle.
Blood flow in the vasa recta is not tightly controlled so it increases with increased renal
perfusion pressure. This causes fluid in the medulla of the kidney to be less able to enter the
vasa recta, resulting in higher renal interstitial hydrostatic pressure. (Granger, 2002; Ivy, 2014)
Another way PN may be regulated is through nitric oxide production. When renal
perfusion pressure rises, intrarenal nitric oxide production increases, which leads to an increase
in water and sodium excretion by inhibiting tubular sodium reabsorption. (Granger, 2002) As a
powerful vasodilator, the increase in nitric oxide also increases renal blood flow and RHIP. It is
unclear exactly how RHIP enhances pressure natriuresis, but there is speculation that it may
result from the release of certain prostaglandins, changes in tight junction permeability to
sodium, or redistribution of apical sodium transporters. (Granger, 2002)
One of the key benefits of pressure natriuresis for blood pressure regulation is that it
responds in direct relationship to sodium levels so that it should be able to compensate for any
amount of variation in sodium intake. However, in some people this is clearly not the case, a
phenomenon often termed salt sensitivity, leading to speculation by some researchers that HTN
results from a shift in the PN relationship so that it does not respond until higher pressures.
6

(Wadei, 2012) Salt sensitivity is more common in older people, African Americans and people
who developed HTN at an early age. It is also associated with obesity where there is
“disturbance of insulin secretion typical of the metabolic syndrome.” (Wadei, 2012) Salt
sensitive people may have a normal glomerular filtration rate or even have normal daytime
blood pressure readings. But they are more likely to have a less marked, or even absent, diurnal
difference in their blood pressure and reduced rates of sodium excretion over night. They also
have a higher risk of certain complications of hypertension, such as micoralbuminuria,
cardiovascular complications and left ventricular hypertrophy. (Wadei, 2012; Ivy, 2014)

2.2 Sugar-Sweetened Beverages and Blood Pressure
Cross-sectional studies of adults have generally supported an association between SSBs
and hypertension, although the results of some studies have not achieved statistical
significance. Table 2.1 summarizes the findings of studies conducted with adult subjects.
Dhingra and colleagues (2007) conducted a cross-sectional study using data gathered as part of
the Framingham Heart Study. The primary outcome of interest in the study was metabolic
syndrome, but the individual components, one of which is hypertension, were also analyzed
separately. They defined elevated blood pressure as >135/85mmHg or on antihypertensive
medication and compared those meeting that criteria who were consuming greater ≥1 SSB per
day to those drinking <1 per day. They found an 18% increased risk of elevated BP (OR: 1.18,
95% CI, 0.96 to 1.44), which was not statistically significant. The model was adjusted for age,
sex, physical activity, smoking, dietary intake of saturated fat, trans fat, fiber, magnesium, total
calories, and glycemic index.
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A 2011 study by Brown and colleagues examined data collected as part of the
International Study of Macro/Micronutrients and Blood Pressure (INTERMAP), which was
gathered in 10 communities in the US and the UK. SSB consumption was assessed by 24-hour
recall and BP was directly measured. Their analysis of 2,696 subjects found an increase of
1.05mmHg (95% CI: 0.50-1.60) in systolic blood pressure(SBP) per 1 serving (355mL) per day in a
model adjusted for energy, urinary sodium, potassium, dietary alcohol, cholesterol,
polyunsaturated and saturated fatty acids, weight and height. However, these results were also
not statistically significant. Artificially sweetened beverage intake was also analyzed and found
to have an inverse relationship with blood pressure (Brown, 2011). The following year, Kim and
colleagues had similar findings from a study looking at data from the 2003-2006 cycles of the
National Health and Nutrition Examination Survey (NHANES). Participants with a previous
diagnosis of HTN were excluded, leaving 3,044 subjects over the age of 19, 357 of whom were
found to have BP in the hypertensive range at the NHANES examination. SSB intake was
assessed by food frequency questionnaire (FFQ) and blood pressure was directly measured. The
fully adjusted model, which accounted for age, gender, NHANES period, BMI, total caloric
intake, race, pack years of smoking, alcohol drinking, sodium/potassium intake ratio, physical
activity, levels of education and history of diabetes, looked at the odds ratio of HTN by level of
SSB intake. They found an odds ratio of 1.21 (0.81-1.81) for 1 time per month-<3 times per
week, 1.39 (0.86-2.24) for 3 times per week-<1 times per day, 1.26 (0.80-1.98) for 1-<3 times per
day, and 1.50 (0.84-2.68) for ≥3 times per day compared to the reference group of <1 time for
month with a p-value of 0.33 for the trend (Kim, 2012). As with Brown et al’s study, the findings
are suggestive of a connection between SSBs and HTN but they are not statistically significant.
A more recent cross-sectional study from 2015 was conducted by Ejtahed and
colleagues in Iran. The main focus of the study was the relationship between SSBs and metabolic
8

Table 2.1: Observational studies of SSBs and BP in adults.
First
Year
Country
Author
Cross-sectional Studies
Brown
2011
U.S. and
U.K.

Population

SSB
categories

BP
categories

Adults, Age
40-59, n=2696

1 (355mL)
serving/day

SBP up
1.05mmHg

OR

Stat.
Sig.
NS

Dhingra

2007

U.S.

6039 personobservations,
3470 in
women; mean
age 52.9 years

≥1/day
vs. <1 per
day

>135/85
mmHg or
anti-HTN
meds.
vs.
Normal BP

1.18

NS

Kim

2012

U.S.

Adults,
≥19 yrs,
n=3044

<1/month

HTN vs.
normal BP

1.0
(0.53,
1.89)
1.21
(0.81,
1.81)
1.39
(0.86,
2.24)
1.26
(0.80,
1.98)
1.50
(0.84,
2.68)
1.0

NS

1/month to
<3/week
3/week to
<1 /day
1/day to
<3/day
≥3/day

Ejtahed

2015

Cohort Study
Cohen
2012

Meta-Analysis
Jayalath
2015

Iran

Adults,
19-70 yrs,
n=5,852

Quartile 1
mean 2.6
g/day
Quartile 2
mean 13.0
g/day
Quartile 3
mean 36.1
g/day
Quartile 4
mean 144
g/day
4th vs. 1st
quartile

HTN vs.
normal BP

P for
trend=0
.02

1.03
(0.85,
1.25)
1.22
(1.01,
1.48)
1.27
(1.03,
1.55)
SBP up
1.8mmHg
DBP up
1.7mmHg

<0.001

U.S.

Adults,
n=253,891

≥1/day vs.
>1/month

Diagnosed
HTN vs.
normal BP

1.13
(1.09,
1.17)

<0.05

U.S. and
Spain

n=240,508

≥1/day vs.
none

HTN vs.
normal BP

1.12
(1.06,
1.17)

<0.05
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syndrome and its components. They examined 5,852 adult men and women who were part of
the fourth phase of the Tehran Lipid and Glucose Study from 2009-2011. They assessed SSB
intake in a slightly unusual way by converting the amount reported on an FFQ into grams. The
participants were then divided into quartiles, with the mean intake for each quartile being 2.6,
13.0, 36.1, and 144 grams of SSB per day. As with Kim et al’s study, they were looking for people
without a previous diagnosis of HTN but with blood pressure in the hypertensive range when
measured by the researchers. They found odds ratios by quartile of SSB intake for elevated BP of
1.03 (CI 0.85-1.25), 1.22 (CI 1.01-1.48) and 1.27 (CI 1.03-1.55). The ORs for the third and fourth
quartiles are statistically significant. Ejtahed et al also examined BP as a continuous variable and
found an increase of 1.8mmHg SBP and 1.7mmHg DBP between the first and fourth quartiles
with a p-value <0.001 for both trends (Ejtahed, 2015).
The results of cohort studies have provided more consistent support for an association
between SSBs and HTN. Cohen and colleagues (2012) conducted a study using data from 3 large
cohorts: The Nurses’ Health Study I, the Nurses’ Health Study II, and the Health Professionals’
Follow-Up Study. The advantage of this approach was that it gave them a very large sample size
of 253,891. They were also able to use self-reported diagnosis of hypertension as their outcome
variable because the participants, who were all health professionals, were unlikely to
misunderstand or misreport a diagnosis. The pooled analysis of these 3 cohorts resulted in a
hazard ratio of 1.13 (95 % CI: 1.09–1.17) for those drinking one or more SSBs per day compared
to less than one per month. The model was adjusted for many confounders including a diet
quality score based on compliance with the DASH diet as well as the more typical items like
alcoholic beverage intake, age, BMI, smoking status and physical activity (Cohen, 2012). In 2015,
Jayalath and colleagues did a meta-analysis of 6 prospective cohort studies (n=240,508) which
examined SSB consumption and HTN. They found a risk ratio of 1.12 (95% CI: 1.06, 1.17) when
10

comparing the highest SSB intake group (≥1 per day) with the lowest intake (none) group. They
also found a dose-response relationship which resulted in a 8.2% increase in risk of HTN with
every additional SSB per day from none to ≥1 SSB per day (β = 0.0027, P < 0.001) (Jayalath,
2015).
Adolescents have been the focus of many studies on the relationship between SSBs and
HTN or metabolic syndrome, summarized on Table 2.2. Three of the four cross-sectional studies
reviewed showed
Table 2.2: Observational studies of SSBs and BP in adolescents.
First Author

Year

Country

Cross-sectional Studies
Bremer
2009
U.S.

Population

SSB
categories

BP
categories

Adolescents1
2-19yrs,
n=6967
Adolescents
13yrs
n=837
Adolescents
8-10yrs,
>85th BMI
percentile,
n=632
Adolescents
12-18yrs,
n=4867

1 serving per
day

SBP up
0.16mm Hg

0.003

Mean daily
intake

No stat. sig.
difference
found in BP
SBP up
1.1mmHg

NS

0 oz/day vs.
>36 oz/day

SBP up
z-score 0.18
(about
2mmHg)

0.03

>130/85
mmHg or
anti-HTN
meds. vs.
Normal BP
No stat. sig.
difference
found in BP
HTN vs.
Normal BP

Loh

2016

Malaysia

Wang

2013

Canada

Nguyen

2009

U.S.

Cohort Studies
Duffey
2010

U.S.

Adolescents
n=2639

Highest vs.
lowest
intake
quartile

Ambrosini

2013

Australia

Tertiles

Mirmiran

2015

Iran

Adolescents
14-17yrs,
n=1433
Adolescents
6-18yrs,
n=439

100mL

Highest vs.
lowest
intake
quartile

11

OR

Stat.
Sig.

0.001

1.06
(1.01,
1.12)

0.023

NS

2.74
(1.05,
7.19)

P for
trend
=
0.018

a statistically significant relationship, but the effect size was small ranging from a 0.16mmHg
increase in SBP per SSB per day to 2mmHg increase in SBP in the highest compared to the lowest
intake groups (Bremer, 2009, Loh, 2016, Wang , 2013, Nguyen , 2009). One study examined the
effect in overweight or obese versus normal weight adolescents and found a 1.1mmHg higher
mean SBP for the highest SSB intake group in the overweight and obese group but no effect in
the normal weight group (Wang, 2013). Cohort studies had more mixed results. One study
looked at SSB consumption averaged for years 0-7 of the study and compared it to prevalence of
HTN at 20 years of follow up. They found a 6% increase risk of HTN (RR: 1.06, 95% CI: 1.01-1.12,
p-value 0.023) for highest versus lowest quartile of SSB intake (Duffey, 2010). A smaller study
(n=439) done in Iran found a stronger association when comparing the highest to lowest quartile
of intake with an OR of 2.74 (95 % CI: 1.05–7.19) for HTN. However, when the data were
analyzed with SSB intake as a continuous variable, the relationship was no longer significant
(Mirmiran, 2015). A cohort study done in Australia found no association (Ambrosini, 2013).
Very few intervention studies, summarized on Table 2.3, have examined the impact of
lowering SSB intake on HTN. Maersk and colleagues (2012) did a randomized controlled trial
primarily looking at the impact of various beverages on liver adiposity in overweight subjects.
They found a non-statistically significant increase in BP in subjects fed 1L of sucrose-sweetened
beverage per day for six months. However, there were only 10 subjects in the SSB test group
(Maesrk, 2012). Some cohort studies have collected data on changes in SSB consumption and
the impact on BP. Chen and colleagues (2010) examined the BP-lowering effect of decreased
SSB consumption on the PREMIRE cohort, a multi-center trial examining the impact of various
lifestyle treatments on patients with pre-hypertension or stage 1 HTN. The wide variety of data
collected during the study allowed Chen et al to control for changes in diet quality, as measured
by DASH adherence, and weight change along with the normal confounders of age, race, etc.
12

The tertile with the greatest reduction in SSB consumption showed a reduction in SBP of
9.5±4.3mmHg, reduction in DBP of 6.3±2.9mmHg, with 23.5% of participants in this tertile
moving from the hypertensive to normotensive BP range over the 18 months of the study. There
was also a statistically significant trend across the tertiles for all of these results (Chen, 2010).
Two studies have analyzed data from the SUN cohort, which included data on increase and
decrease in SSB consumption over the six year course of the study. Barrio-Lopez and colleagues
(2013)
Table 2.3: Assessing effect of change in SSB intake over time.
First Author

Year

Country

Randomized Controlled Trial
Maersk
2012
Denmark

Population

SSB
categories

BP
categories

n=10 in each
group

1L sucrosesweetened
beverage per
day for six
months

No stat. sig.
difference
compared
to water
group

NS

SBP up
0.7mmHg
(0.12, 1.25)
DBP up
0.4mmHg
(0.02-0.75)
Selfreported
HTN or use
of anti-HTN
meds.
Selfreported
HTN or use
of anti-HTN
meds.

NS

Cohort Studies
Chen
2010

U.S.

pre-HTN or
stage 1 HTN,
n=810

Per 1
serving/day
decrease

Barrio-Lopez

2013

Spain

Adults,
n=8157

Sayon-Orea

2015

Spain

Adults,
n=13,843

Largest
increase vs.
largest
decrease
quintile
Largest
increase vs.
no change

OR

Stat.
Sig.

1.60
(1.3,
2.1)

P for
trend
<
0.001

1.26
(1.02,
1.55)

<0.05

were looking at MetS and its components and found that participants with the highest increase
in SSB consumption had 60% increased risk developing HTN compared to those in largest
decrease quartile (OR: 1.6, 95 % CI 1.3, 2.1; P for trend < 0·001). This study was conducted in
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Spain and they attempted to control for adoption of an overall American diet but adding French
fries, red meat, fast food and adherence to a Mediterranean dietary pattern to the confounders
controlled for, as well as the more typical total energy intake, smoking, physical activity and
alcohol intake (Barrio-Lopez, 2013). Two years later, Sayon-Orea and colleagues (2015)
conducted a study using the same data set but looking specifically at HTN. Their analysis was
slightly different because they looked at the incidence of HTN in participants who increased SSB
consumption versus those whose intake did not change, rather than increase compared to
decrease in SSB intake. Predictably, the association was also positive but weaker, with a 26%
increased risk of HTN (OR: 1.26, 95% CI: 1.02–1.55) (Sayon-Orea, 2015).
The majority of published findings do support a positive association between SSB intake
and elevated BP and the risk of HTN, both in adults and adolescents (Barrio-Lopez, 2013;
Bremer, 2009; Cohen, 2012; Duffey, 2010; Ejtahed, 2015; Jayalath,2015; Mirmiran, 2015;
Nguyen, 2009; Sayon-Orea, 2015; Wang, 2013). Of the studies that did not find a statistically
significant association, more than half found a non-significant positive correlation (Brown, 2011;
Chen, 2010; Dhingra, 2007; Kim, 2012). The OR for development of elevated BP or HTN ranged
between 1.06 (Duffey, 2010) and 2.74 (Mirmiran, 2015) for studies with a statistically significant
finding. Large 95% confidence intervals in some of the reported odds ratios (Barrio-Lopez, 2013;
Kim, 2012; Mirmiran, 2015) suggest that there may be quite a bit of heterogeneity in individuals’
BP response to SSB intake. Those studies which examined BP as a continuous variable found an
increase of 0.16mmHg (Bremer, 2009) to 1.1mmHg SBP (Wang, 2013) per additional serving of
SSB per day, which suggests that the effect may only be medically significant in heavy users of
SSBs.
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2.3 Sugar-Sweetened Beverages and Uric Acid
The most frequently discussed mechanism by which SSBs are thought to increase blood
pressure is through elevating serum uric acid levels (Brown, 2011; Ejtahed, 2015; Jayalath, 2015;
Kim, 2012; Nguyen, 2009). The reason for this is that SSBs are a very rich dietary source of
fructose. After ingestion, fructose is transported to the liver where it is phosphorylated by
fructokinase to form fructose-1-phosphate, using a phosphate group from an ATP. This reaction
is not well regulated and will continue as long as fructose is present. Eventually, it can lead to
depletion of ATP, and then ADP and AMP until only the adenosine remains. Adenosine will be
broken down by the purine pathway with

Figure 2.1: Uric acid metabolism.

the final product being uric acid. A key
enzyme in this pathway, illustrated in
Figure 1, is xanthine oxidase, which
catalyzes the final two steps. Humans do
not produce the enzyme uricase that would
further degrade uric acid into allantoin,
which leads to an approximately 10 times
higher serum UA than most other
mammals. While hyperuricemia is
associated with many diseases, especially
gout, UA also functions as an important
antioxidant and is inversely associated with
Reproduced from:
Asghar, Z. A., Thompson, A., Chi, M., Cusumano, A.,
Scheaffer, S., Al-Hammadi, N., ... & Moley, K. H. (2016).
Maternal fructose drives placental uric acid production
leading to adverse fetal outcomes. Scientific reports, 6.

some disease such as Parkinson’s Disease
and other neurodegenerative diseases. UA
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is ultimately removed by the kidneys through active excretion and through the gastrointestinal
tract (Mandal, 2015).
Uric acid has been shown to have a relationship with hypertension in studies such as
one conducted by Sundstrom and colleagues (2005), which examined 3329 middle-aged
Framingham Heart study participants and found a 17% increased risk (OR: 1.17, 95% CI: 1.021.33) for developing HTN at 4 years of follow-up per 1 standard deviation elevation in baseline
UA levels. Another 2005 study by Alper and colleagues looked at 577 participants in the
Bogalusa Heart Study. Age at baseline was between 5 and 17 years and subjects were followed
for an average of 12 years. They found a strong correlation between UA levels in childhood and
both childhood and adult elevated BP, with a stronger association observed in females than
males (Alper, 2005). In a randomized controlled trial of allopurinol, a xanthine oxidase inhibitor,
Feig and colleagues (2013) investigated whether lowering UA had a BP-lowering effect in 30
adolescents with incident stage 1 HTN. Participants had a 6.3 mmHg (95% CI: 3.8−8.9 mmHg)
reduction in mean 24-hour SBP and 4.6 mmHg (95% CI: 2.4−6.8 mmHg) reduction in mean 24hour DBP during the treatment compared to the placebo phase of this cross-over study. Those
reductions are consistent with what could be expected from standard antihypertensive drug
therapies (Feig, 2013).
The mechanism for the impact of uric acid on BP has been investigated using animal
models. Mazzali and colleagues (2001) developed a rat model to look at mild hyperuricemia,
more similar to the UA levels seen in humans than earlier rat models, which resulted in as much
as a 10-fold increases in UA, acute kidney injury and death. The hyperuricemic rats in Mazzali’s
study had a more modest 2-3-fold increase and did show an increase in BP over the study
period. Interestingly, the BP difference between hyperuricemic rats and control rats was the
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greatest in rats on a modest salt-restricted diet. BP in rats who had been hyperuricemic and
where then treated to lower UA levels dropped back down into the normal range. When the
kidneys of treated rats were examined, they showed an increase in interstitial collagen
deposition, fibrosis and neutrophil infiltration. Hyperuricemic animals were also found to have
markedly increased renin and decreased nitric oxide synthase. In hyperuricemic rats given an
ACE-inhibitor and the NO-precursor L-arginine, BP was normal and renal injury prevented,
suggesting that the RAAS and NO systems are part of the causal pathway for UA-induced HTN
(Mazzali, 2001). Khosla and colleagues further elucidated this relationship. They induced
hyperuricemia in rats using the same method as in Mazzali et al’s study, and found a 40-50%
decrease in NO production within one day which lasted throughout the seven days of the
experiment. They also preformed and in vitro study with bovine endothelial cells and found a
dose-dependent decrease in NO production with UA exposure (Khosla, 2005).
While the studies discussed above support relationships between fructose, UA and HTN
(Alper, 2005; Feig, 2013; Khosla, 2005; Mandal, 2015; Mazzali, 2001; Sundstrom, 2005;), the
question remains of whether intake from SSBs provides enough fructose and produces enough
UA to activate this pathway. Animal studies have been used to investigate this relationship by
inducing elevated UA and BP through fructose feeding, rather than by inhibiting uricase, and
have found a positive correlation (Sanchez-Lozada, 2007, Nakagawa, 2006). However, very high
levels of fructose, up to 60% of calories consumed, are used to overwhelm the rats’ innate
ability to metabolize uric acid. This level of fructose intake is so far in excess of normal human
consumption some question the applicability of this data in humans (Ha, 2012). Sanchez-Lozada
and colleagues (2007) did include a test group of rats who were fed normal chow but also given
ad-libitum access to 10% fructose-sweetened water, which is somewhat more similar to the way
it is consumed in humans drinking SSBs. These rats were found to have consumed 38±2% of
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their calories from fructose and showed a statistically significant increase in both UA and BP at
the end of the 8 week study, although not as large an increase as the group fed 60% fructose
chow.
Experimental studies examining the impact of high levels of fructose intake on UA and
BP in humans are fairly rare. Wang and colleagues (2012) did a review and meta-analysis of
controlled-feeding trials and found no effect in isocaloric studies but did find a relationship in
hypercaloric trials. One example of such a study was done by Perez-Pozo and colleagues in 2010.
They conducted a randomized controlled study investigating this relationship by feeding
subjects (n=74, all men) 200g of fructose per day for two weeks. Half of the subjects were also
treated with allopurinol, which disrupts the action of xanthine oxidase, a critical enzyme in the
uric acid pathway. The fructose-only group had a statistically significant increase in their uric
acid levels and BP but the fructose-plus-allopurinol group did not have an increase in either
(Perez-Pozo, 2010). In their meta-analysis of three hypercaloric trials, including Perez-Pozo’s
study, Wang et al found a mean increase in UA levels of 0.52 mg/dL (Wang, 2012). These
findings suggest that the SSB-UA pathway might be of concern only with higher intakes of SSBs,
which are more likely to be excess calories.
Cross-sectional studies have tried to determine whether high SSB intake leads to
elevated UA levels or hyperuricemia in free-living humans. Choi and colleagues (2008) examined
the relationship between SSB intake and UA levels in 14,317 NHANES (1988-94) participants free
of gout and UA lowering medications. They found the highest intake group of SSBs, ≥4 servings
per day, had a 0.42mg/dL (95% CI: 0.11, 0.73) higher mean UA level than the reference group (0
servings per day) and an 82% higher risk hyperuricemia (OR: 1.82, P = 0.003 for trend over
quintiles). However, the strength of the association varied by gender: men in the highest SSB
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group had a mean UA 0.52mg/dL higher than the reference group where women had 0.19mg/dL
(Choi, 2008). Gao and colleagues undertook a very similar study with 4,073 participants from the
2001-2002 NHANES survey, and found a 0.22mg/dL mean difference in UA between the highest
and lowest SSB intake quartiles. They also found a striking difference between the genders, as
shown in Figure 2, reproduced here (Gao, 2007).

Figure 2.2: Difference in UA production in response to SSB intake by gender.

Some studies have looked at the impact of SSBs on both UA and HTN. In a study of U.S.
adolescents (n=4,867), Nguyen and colleagues (2009) found that their mean UA was 0.18mg/dL
greater in highest intake quartile (>36oz/day) compared to the lowest SSB intake quartile
(0oz/day). This study also found higher BP in the highest intake group, as reported earlier in this
review. Bobridge and colleagues (2013) conducted a similar study with Australian adolescents
(n=814); however, they looked at total fructose intake rather than SSBs alone. They found a
significant association between energy-adjusted fructose intake and UA in boys but not girls.
While they found no association between fructose intake and BP, they did find an association
between UA and BP in boys but not in girls. (Bobridge, 2013)
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Evidence from animal studies shows that hyperuricemia, even in a fairly mild form,
causes structural changes to the kidney and to renin and NO production that have a significant
impact on blood pressure (Khosla, 2005; Mazzali, 2001). Studies that have used allopurinol to
interrupt UA production and successfully lower BP further bolster this association (Feig, 2013;
Perez-Pozo, 2010). There is also epidemiological and experimental evidence in humans to show
that hyperuricemia is associated with hypertension (Alper, 2005; Sundstrom, 2005). However,
the effect in large, general population studies is less pronounced than might be expected if
extrapolated from animal models (Bobridge, 2013; Nguyen, 2009). Part of this difference could
be attributed to the marked difference between the genders, as seen in the studies by Choi ,
Goa and Bobridge et al.

2.4 Vitamin D and Uric Acid
Vitamin D can be consumed in the diet or it can be synthesized in the skin, where UVB
radiation converts 7-dehydrocholesterol to previtamin D, which spontaneously isomerizes to
vitamin D3 at normal body temperatures. Vitamin D3 is also the form consumed from animalbased dietary sources, whereas plant foods provide vitamin D2. A vitamin D binding protein
transport the vitamin D3 to the liver, where it is transformed to 25-hydroxyviatmin D (25(OH)D).
25(OH)D is the circulating form of vitamin D and plasma levels increase directly in response to
dietary intake or skin synthesis. For this reason, serum 25(OH)D levels are used to determine
vitamin D status. Controversy continues on what constitutes adequate serum vitamin D levels,
but the estimated average requirement set by the Institute of Medicine remains 16ng/dL(40
nmol/L), which is based on the level needed for bone health. However, 25(OH)D is not known to
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have any unique biological function. The kidneys are the main site of activation by the enzyme
1-α hydroxylase to the active form of vitamin D, 1,25-dihydroxyvitamin D (Stipanuk, 2013).
Vitamin D plays a critical role in calcium metabolism and bone health by facilitating
absorption of calcium in the intestine, reabsorption in the kidneys and regulation of bone
mineralization and remodeling. However, in recent years vitamin D receptors have been found
in many other tissues throughout the body. Epidemiological evidence has suggested links with
cancer, diabetes, and heart disease etiology and progression (Stipanuk, 2013). Vitamin D
impacts blood pressure through its role in renin gene transcription and endothelial function
(Min, 2013).
2.4.1 25-hydroxyvitamin D
Numerous studies have focused on the potential association between serum vitamin D
levels as 25-hydroxyvitamin D (25(OH)D) and uric acid levels. Table 2.4 shows the results of
observational studies that examined this relationship by measuring mean serum UA levels
across 25(OH)D categories. In a cross-sectional study of UA and vitamin D status in middle-aged
and elderly Chinese Han women (n=1,726), Peng et al found an association in post-menopausal
(>55 years) but not pre-menopausal women (<55 years). The risk of elevated UA (>90th
percentile) was nearly 2.5 times greater among post-menopausal women with suboptimal
vitamin D status (<30ng/mL, <75nmol/L) than in women with sufficient vitamin D status (OR:
2.38; 95% CI: 1.47, 3.87) (Peng, 2012).
Several other studies did not examine the relationship between 25(OH)D and UA as a
primary objective but did include measurements of this association among their reported
results. Another cross-sectional study conducted by Alemzadeh and colleagues of 152 obese
adolescents aged 13-19 years in the United States had the primary objective of ascertaining
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whether there was an association between UA and parathyroid hormone levels (PTH) or
PTH:25(OH)D ratio. With subjects stratified by vitamin D sufficiency (≥30ng/mL), insufficiency
(20-29.9ng/mL) and deficiency, (<20ng/mL), Alemzadeh et al found UA levels increased as
25(OH)D levels decreased (5.4 ± 1.1, 6.0 ± 1.2, and 6.5 ± 1.2mg/dL respectively, p-value of
0.0007) (Alemzadeh, 2016).
Table 2.4: Observational studies of impact of difference in 25(OH)D on UA
First Author

Year

Country

Cross-sectional Studies
Alemzadeh
2016
U.S.

Peng

2012

China

Population

25(OH)D
Levels,
ng/mL

Serum Uric
Acid,
mg/dL

Adolescents,
13-18yrs,
obese n=152

Sufficient,
≥30

5.4 ± 1.1

Insufficient,
20-29.9
Deficient,
<20
>30

6.0 ± 1.2

≤30

Elevated,
≥5.3, >90th
%tile
Normal

Women,
<55yrs
n=858
Women,
>55yrs
n=868

>30
≤30

OR

Stat.
Sig.

0.0007

6.5 ± 1.2
Normal

Elevated,
≥6.0, >90th
%tile

1.0
(0.53,
1.89)

NS

2.38
(1.47,
3.87)

0.001

Studies where vitamin D levels were controlled or manipulated all found no association
between vitamin D and UA (Table 2.5). A 1974 animal study conducted by Al-Gauhari and
colleagues, which was designed to assess the impact of vitamin D deficiency on protein
metabolism, found no statistically significant difference in UA between rats fed a normal diet
and a vitamin D-deficient diet and isolated from all sun exposure for 45 days (4.5±0.2 vs
4.8±0.2mg/dL, p-value NS) (Al-Gauhari, 1974). Intervention trials with humans which
supplemented vitamin D and then measured uric acid also found no effect. Lind and colleagues
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examined the metabolic impacts of supplementation of 1mg of alphacalcidol (1(OH)D) daily on
42 adults with hypertension in Sweden. They found no statistically significant difference in UA
Table 2.5: RTC and intervention studies of impact of difference in 25(OH)D on UA.
First Author

Year

Animal Study
Al-Gauhari
1974

Country

Population

Vitamin D
Levels, ng/mL

Serum Uric Acid,
mg/dL

Stat. Sig.

Egypt

albino rats
50% male
n=20

Deficient

4.5±0.2

NS

Non-deficient

4.8±0.2

Women,
>65yrs,
baseline D
≤12 ng/mL,
n=192
Adults w/
HTN
n=42,
groups
matched for
age and sex

Supplement 28.75 (23.2535.75) M(IQ)
Placebo - 10.75
(8.00-14.0)
Treatment
(1mg 1(OH)D/
day), before
Treatment,
after

5.3 (4.0, 6.1)

Control, before

5.7±0.8

Control, After

5.6±0.8

Randomized Controlled Trials
Brazier
2005
France

Lind

1991

Sweden

NS

4.9 (3.9, 6.1)
NS
5.7±1.3
5.9±1.2

levels between either group before and after the study (treatment before 5.7±1.3, after 5.9±1.2;
control before 5.7±0.8, after 5.6±0.8mg/dL, p-value NS) or between the treatment and control
groups. (Lind, 1991) In a year-long supplement trial, Brazier and colleagues assessed the safety
of a calcium and vitamin D supplement (500mg CaCO3, 400 IU cholecalciferol twice daily) in a
group of French women over age 65 (n=192). The treatment group had 25(OH)D levels of
28.75ng/mL (23.25-35.75) (median, interquartile range), putting them in the insufficient range,
and the placebo group of 10.75ng/mL (8.00-14.0), putting them in the deficient range. These
two groups had UA levels of 5.3mg/dL (4.0, 6.1) and 4.9mg/dL (3.9, 6.1) respectively, with a pvalue on the t-test of 0.603. Interestingly, more participants were outside the normal range (UA
>5.7mg/dL) in the treatment group versus the placebo group (46 (52.3%) vs 32 (37.2%), 2 p-
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value 0.05) (Brazier, 2005). Other studies which found an association between vitamin D and UA
levels found the opposite effect (Alemzadeh, 2016; Peng, 2012).
Looking at the vitamin D/Uric Acid relationship with UA as the exposure variable (Table
2.6) did not change the relationships identified in the studies by Peng et al and Alemzadeh et al.
Peng and colleagues defined elevated serum UA as greater than or equal to the 90th percentile
for that group, 5.3mg/dL in pre-menopausal and 6.0mg/dL in post-menopausal women. There
was no statistically significant difference in 25(OH)D levels in pre-menopausal women (40(3351)ng/mL vs 41(36-54)ng/mL, median (interquartile range), p-value 0.364) but in postmenopausal women vitamin D levels were lower in women with elevated UA (40(32-58)ng/mL
vs 35(28-57)ng/mL, p-value 0.006) (Peng, 2012). Alemzadeh and colleagues also defined
elevated uric acid as ≥6.0mg/dL. They found that subjects with elevated uric acid levels had
statistically significantly lower levels of 25(OH)D (19.2 ± 8ng/mL vs 23.2 ± 8.4ng/mL, p-value
0.0027). (Alemzadeh, 2016) Contrary to the findings of Peng and Alezadeh’s studies, Hernández
and colleagues did not find an association between UA and vitamin D. They conducted a cohort
study of men over 50 (n=868) to look at uric acid and bone density. While this was a cohort
study, for the purposes of this review it is a cross-sectional study because they only examined
the 25(OH)D and UA levels in participants at baseline, so we only have a snap-shot association
between UA and vitamin D levels. In that measurement, 25(OH)D levels in men did not differ
(23.0 ± 8.1ng/mL verses 22.9 ± 8.1ng/mL, p-value 0.96) by UA level above or below the median
(6.0mg/dL)for the cohort (Hernández, 2015). In contrast to the analysis where vitamin D was the
exposure variable, the UA levels used between studies is the same in all but one case, with
6.0mg/dL as the cutoff between normal and elevated. Although this common factor makes the
results much easier to compare, the relationship between higher UA levels and 25(OH)D levels
remains unclear.
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Table 2.6: Observational studies of impact of difference in UA on 25(OH)D.
First Author

Year

Country

Cross-sectional Studies
Alemzadeh
2016
United
States
Hernández

Peng

2015

2012

Spain

China

Population

Serum Uric
Acid, mg/dL

25(OH)D Levels,
ng/mL

Stat. Sig.

Adolescents,
13-18yrs,
obese n=152
Men, >50yrs
n=868

Normal, <6.0

23.2 ± 8.4

0.0027

Elevated, ≥6.0

19.2 ± 8

below median,
<6.0
above median,
>6.0
Normal

23.0±8.1

Elevated, ≤5.3,
<90th %tile
Normal

41(36, 54)

Elevated, ≤6.0,
<90th %tile

35(28, 57)

Women,
<55yrs
n=858
Women,
>55yrs
n=868

0.96

22.9±8.1
40(33, 51) M(IQ)

40(32, 58)

0.364

0.006

2.4.2 1,25-Dihydroxyvitamin D and 1-α hydroxylase
Fewer studies have examined the relationship between 1,25(OH)D and UA, but they
have consistently found an association (Table 2.7). Two animal studies explored the hypothesis
that high uric acid levels interfere with vitamin D by inhibiting the enzyme, 1-α hydroxylase,
responsible for the final step in converting vitamin D to its active form, calcitriol (1,25(OH)2D).
Hsu and colleagues (1991) conducted an animal study to determine whether purine
metabolites, including UA, would impact calcitriol metabolism. They found that infusion of male
rats (5 per group) with 20 mL of 50mg/dL sodium urate solution led to a statistically significant
decrease in calcitriol concentration compared to saline-infused controls (control: 229.58±12.22
vs treatment: 147.68±10.66pmol/L). Similarly, Chen and colleagues (2014) examined 25 male
Sprague–Dawley rats divided into 4 groups. One group was treated with a substance that
elevated uric acid levels by inhibiting uricase, one group was treated with a substance that
reduced uric acid by inhibiting xanthine oxidase, one group was treated with both substances
and one group served as an untreated control. All rats were killed 24 hours after treatment,
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calcitriol levels and the ratio of 25(OH)D to 1,25(OH)D was measured and kidneys were
examined. The hyperuricemic rats were found to have lower serum calcitriol (control: 836±56 vs
hyperuricemic: 708±73 pmol/L, p-value 0.0055), lower 1,25(OH)D:25(OH)D ratios in serum (pvalue 0.021) and lower levels of 1-α hydroxylase in their kidneys as measured by
immunofluorescence compared to controls (5.7 vs 11.4 in controls, arbitrary units, p-value
0.015). Their levels of 25(OH)D were also lower but this difference was not statistically
significant (p-value 0.095) (Chen, 2014).
Chen and colleagues also preformed an in vitro cell culture study of human kidney
tubules treated with different doses of uric acid and examined them after 24 hours. The UAtreated tubule cells had 50% less 1-α hydroxylase mRNA compared to untreated controls (pvalue-0.01). While all treated cells showed reduced mRNA, only the cells treated with the
highest dose, 10mg/dL of UA, had significantly lower levels of 1-α hydroxylase protein in the 24
hour time period (p-value- 0.02). Cell changes were also examined with 10 mg/dL of uric acid
over different lengths of time, up to 24 hours. Expression of mRNA decreased over 6 hours and
then remained steady at 62% of control level (p-value-0.049). Protein expression reached its
lowest point after 16 hours at 23% of control and rebounded slightly to 36% after 24 hours (pvalue 0.02). Chen et al suspected that the mechanism involved was that uric acid activated
nuclear factor κ-B which in turn suppressed 1-α hydroxylase, based on previous studies. To test
this, they pre-treated cell cultures with a nuclear factor κ-B inhibitor and found that the impact
of uric acid on 1-α hydroxylase was eliminated.
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Table 2.7: Animal and cellular studies of impact of UA on 1,25-Dihydroxyvitamin D and
1-α hydroxylase.
First
Author

Year

Country

Population

1,25(OH)D
pmol/L

Serum Uric
Acid, mg/dL

Animal Studies
Hsu
1991

U.S.

Rats
5 per group

Chen

U.S.

Rats
n=25
Rats
n=25

229.58±12.22
147.68±10.66
836 ± 56
708 ± 73

1.1±0.1
4.2±0.3
1.9 ± 0.1
3.3 ± 1.4
1.9 ± 0.1
3.3 ± 1.4

11.4
5.7

0.015

Control
10

8.8
3 .3

0.002

2014

Cellular Studies
Chen
2014

U.S.

Human
Kidney
Tubules

1-α
hydroxylase,
arbitrary
units

Stat.
Sig.

<0.001
0.0055

2.4.3 Parathyroid Hormone (PTH)
Studying the relationship between UA and 1-α hydroxylase in humans presents a
challenge because 1,25(OH)D is difficult to measure in humans due to its short half life. It is also
only present when called for by the presence of parathyroid hormone. However, if 1,25(OH)D
production does not increase in response to PTH, PTH levels will continue to rise, thus making
elevated PTH levels a proxy measurement for low 1,25(OH)D levels, either because not enough
precursor, 25(OH)D, is present or because 1-α hydroxylase has been inhibited (Chen, 2014).
Table 2.8 summarizes the results of studies that looked at the association between PTH and UA.
Chen et al performed a cross-sectional analysis on the 9005 participants in NHANES 2003-2006
over the age of 18 without kidney disease and with complete data including serum PTH and uric
acid. Many potential confounders were included in the analysis, including age, sex, race and
ethnicity, diabetes, hypertension, BMI, and serum 25(OH)D concentration. The odds ratio for
elevated PTH (>65pg/mL) for every 1 mg/dL increase in uric acid was 1.15 (95% CI: 1.08-1.22; P <
0.0001), adjusted for confounders. This relationship was independent of 25(OH)D levels. These
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results suggest an association between elevated UA levels and inhibition of 1-α hydroxylase,
leading to low 1,25(OH)D and then to elevated PTH.
Some of the cross-sectional studies discussed in earlier sections of this review examined
PTH and UA levels. This relationship was the focus of the study conducted by Alemzadeh et al
(2016). They found that adolescents with elevated UA (≥6.0mg/dL) had higher mean PTH levels
than those with normal UA (50.5±12.3 vs 35.7±14.7pg/mL, p-value <0.0001). They also found
those with elevated UA had a higher PTH:25(OH)D ratio(1.35±0.9 vs 0.75±0.5, p-value <0.0001)
suggesting that they were making less 1,25(OH)D from the same amount of 25(OH)D. Hernández
and colleagues (2015) also found marginally statistically significant higher PTH levels (52.8
(42.1–65.0)pg/mL vs 50.9 (39.3–63.2)pg/mL, median(interquartile range), p-value-0.05) for
those above versus below the median UA level of 6.0mg/dL.
An earlier cross-sectional study of PTH and UA, conducted by Hui et all (2012), found the
odds ratio for elevated UA levels (>7mg/dL in men, >5.7mg/dL in women) to increase by quintile
of PTH (OR 1.0, 1.07, 1.22, 1.36, 1.39, p-value 0.03 for trend) in the fully adjusted model, which
accounted for age, sex, race, BMI, use of diuretics, allopurinol and uricosuric agents,
hypertension, serum levels of calcium, alkaline phosphatase, phosphorus, vitamin D; and
glomerular filtration rate as well as total daily intake of alcohol, energy, protein, sugar, and
caffeine. Chin and colleagues (2015) conducted a similar cross-sectional study in Malaysian men
(n=320) and found that elevated PTH (> 65 pg/mL) levels were positively associated with
hyperuricemia(>7.0mg/dL), but the effect size was very small and may not be clinically
important (OR 1.045 (1.017-1.075) p-value 0.002). Their model was adjusted for age, body mass
index, ethnicity, serum 25(OH)D, blood urea nitrogen, and creatinine level. A study by Paik and
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Table 2.8: Observational studies of association between PTH and UA.
First
Author

Year

Country

Cross-Sectional Studies
Alemzadeh 2016
U.S.

Chen

Chin

Hernández

Hui

2014

2015

2015

2012

U.S.

Malaysia

Spain

U.S.

Population

PTH Levels
pg/mL

Serum Uric
Acid, mg/dL

Adolescents,
13-18yrs,
obese n=152

35.7 ± 14.7

Normal,
<6.0

50.5 ± 12.3

Adults
n=9773

≤65

Elevated,
≥6.0
5.2± 1.4

> 65

5.9 ±1.6

Men,
>20yrs,
n=380

Normal
PTH, 10-65

Normal,
≤7.0

Increased
PTH, > 65

Hyperurice
mic, >7.0

Men, <50yrs
n=868

50.9 (39.3–
63.2)

below
median,
<6.0

52.8 (42.1–
65.0)

above
median,
>6.0
Normal vs
Elevated,
>7.0 in men,
>5.7 in
women

Adults,
>18yrs
n= 8,316

Quantile 1,
6-27
Q 2,
28-36
Q 3,
37-44
Q 4,
45-58
Q5
59-491

Paik

2012

U.S.

Adults,
White,
n=4026
Adults,
Black,
n=1792
Adults,
MexicanAmerican,
n=1834

Increase of
4.9(2.7-7.0)
in Q4 vs Q1
Increase of
5.5(3.0-8.1)
in Q4 vs Q1
Increase of
4.8(1.5-8.1)
in Q4 vs Q1
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OR

Stat. Sig.

<0.0001

1.21
(1.14,
1.28) per
1 mg/dL
(59.48
μmol/L)
UA
1.05
(1.02,
1.08)

< 0.0001

0.002

0.05

1,
referent
1.07
(0.77,
1.49)
1.22
(0.81,
1.82)
1.36
(1.03,
1.80)
1.39
(1.03,
1.88)

0.03 for
trend

Quartile1:
<4.3

<0.01 for
trend

Quartile 4:
≥6.1

<0.01 for
trend
0.02 for
trend

colleagues (2012) investigating the impact of various factors on PTH levels found that PTH levels
differed by race. They calculated the increase in PTH by quartiles of UA and found that, in the
fourth compared to the first quartile, non-Hispanic Whites had an increase of 4.9pg/mL (95% CI:
2.7-7.0pg/mL) (p-value for trend <0.01), Blacks had an increase of 5.5pg/mL (95% CI: 3.08.1pg/mL) (p-value for the trend <0.01), and Mexican-Americans had an increase in PTH of
4.8pg/mL (95% CI: 1.5-8.1pg/mL) (p-value for the trend 0.02). Despite their small differences, all
groups showed an association between PTH and UA. The results of these three studies support
the hypothesis that UA raises PTH levels via inhibition of 1-α hydroxylase, although caution must
be used in interpreting the results of cross-sectional studies.

2.5 Discussion
A positive association between SSB intake and elevated BP and HTN is supported by the
literature, but the association is not very strong in most studies (Barrio-Lopez, 2013; Bremer,
2009; Cohen, 2012; Duffey, 2010; Ejtahed, 2015; Jayalath, 2015; Mirmiran, 2015; Nguyen, 2009;
Sayon-Orea; 2015; Wang, 2013). Marked heterogeneity, as evidenced by wide 95% confidence
intervals (Barrio-Lopez, 2013; Kim, 2012; Mirmiran, 2015), may have contributed to this and
suggests that while the impact of SSB intake on BP may be small at the population level, for
some people it may play a much larger role. UA production differs between men and women in
response to SSB intake (Bobridge, 2013; Choi, 2008; Gao, 2007), which provides one possible
mechanism for that heterogeneity. Another possible difference being explored in this review is
whether vitamin D status interacts with SSB intake or the UA produced in response to high SSB
intake.
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Of studies examining a possible relationship between vitamin D and uric acid, those
looking at 25(OH)D are the most numerous and the most inconclusive (Alemzadeh, 2016; AlGauhari, 1974; Brazier, 2005; Hernández, 2015; Peng, 2012). Looking at analyses with either
25(OH)D or UA as the outcome variable, associations were found in post-menopausal Chinese
women (Peng, 2012) and a mixed gender group of American adolescents (Alemzadeh, 2016). No
association was found in pre-menopausal Chinese women (Peng, 2012), Spanish men over age
50 (Hernández, 2015), or French women over age 65 taking part in a supplement trial (Brazier,
2005). An animal study examining 25(OH)D and UA also found no association (Al-Gauhari, 1974).
The only unifying feature seems to be that studies conducted specifically to look at the
relationship between 25(OH)D and uric acid, or the related topic of PTH and UA, found an
association (Alemzadeh, 2016; Peng, 2012) and those that looked at the two factors incidentally
did not (Brazier, 2005; Hernández, 2015). One possible cause of this could be publication bias.
Studies with null findings are less likely to be published, so it may have been easier for studies
that did not find an association to be published if this null result was not their primary outcome
measurement. While two of the studies examining metabolic changes in general did have overall
null findings, their primary objective was to examine the safety of supplements, so observing no
change in metabolic parameters can be regarded as a success in these cases. Therefore, there
may be more data showing no association that were not available for this review, which would
further weaken the case that there is a true association between 25(OH)D and uric acid.
Few studies have investigated the relationship between 1,25(OH)D, 1-α hydroxylase or
PTH and UA, but these studies have consistently found an association (Alemzadeh, 2016; Chen,
2014; Chin, 2015; Hernández, 2015; Hsu, 1991; Hui, 2012; Paik, 2012). On the other hand,
1,25(OH)D and 1-α hydroxylase studies have only been conducted in animal models and in vitro
(Chen, 2014; Hsu, 1991). The studies looking at PTH are all cross-sectional (Alemzadeh, 2016;
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Chen, 2014; Chin, 2015; Hernández, 2015; Hui, 2012; Paik, 2012), so it is impossible to assess
temporality in the relationship. Chen and colleagues made the case that elevated PTH levels
represented inhibition of 1-α hydroxylase by high UA levels (Chen, 2014). However, Hui and Chin
and colleagues had a different interpretation. They saw the association of PTH and UA as
evidence that elevated PTH levels inhibit the urinary excretion of UA, and therefore
hyperparathyroidism can lead to hyperuricemia (Chin, 2015; Hui, 2012;). They based this
hypothesis on other studies showing the UA-lowering effects of either treating primary
hyperparathyroidism with parathyroidectomy (Hisatome, 1992) or cessation of synthetic PTH
used to treat bone disease (Miller, 2007). This hypothesis opens up the possibility of a positive
feedback loop where low 25(OH)D levels cause an increase in PTH, which then blocks the
excretion of UA, which inhibits the production of 1,25(OH)D and further increases PTH. On the
other hand, most of the studies that looked at the PTH/UA relationship controlled for 25(OH)D
levels (Alemzadeh, 2016; Chen, 2014; Chin, 2015; Hui, 2012; Paik, 2012), which suggests that
there may have been some other factor in the initial rise in UA (Figure 3). Further study will be
needed to determine whether that other factor might be sugar-sweetened beverage intake. The
practical implications of this proposed pathway is that both lowering SSB intake as well as
vitamin D repletion may be needed to short-circuit this pathway and rule it out as a contributor
to elevated blood pressure.
The purpose of this review was to determine whether available evidence supports a
possible interaction between vitamin D status and sugar-sweetened beverage intake in their
impact on blood pressure and hypertension risk. Could good vitamin D status protect against the
impact of high SSB intake on HTN? Based on the results of the review, this association seems
unlikely (Al-Gauhari, 1974; Brazier, 2005; Hernández, 2015; Peng, 2012). If high SSB intake can
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Figure 2.3: Proposed pathway.

suppress 1-α hydroxylase by raising UA, vitamin D would still be unable to fulfill its role in BP
regulation, even if high levels of 25(OH)D were present. Could high SSB intake nullify the
positive effect of vitamin D repletion? This scenario seems more likely. If subjects with high SSB
intake where unable to make use of the 25(OH)D, it would be unable to lower their blood
pressure. Even if other subjects did experience a BP-lowering effect, that relationship would be
obscured by the within-group variability introduced by not stratifying the results according to
SSB intake. However, this is merely conjecture, as no published research looks at all the steps in
this pathway. The proposed study will examine all of these factors - SSBs, UA, vitamin D, PTH
and HTN - in the same subjects to test the hypothesis that an interaction between SSB and
vitamin D influences the association of each variable with HTN. Understanding these
relationships will bring us one step closer to understanding the etiology of primary
hypertension.

33

CHAPTER 3
HYPOTHESES AND SPECIFIC AIMS

1. Sugar-sweetened beverage intake will be positively associated with SBP in men and women
aged 20-74 years from NHANES 2003-2006. Uric acid will play a mechanistic role in that
association.
Specific Aim 1: SSB intake will be positively associated with elevated systolic blood
pressure when assessed with linear and logistic regression adjusted for age,
race/ethnicity, BMI, leisure time physical activity, smoking and alcohol use.
Specific Aim 2: SSB intake will be positively associated with serum uric acid (mg/dL).
Specific Aim 3: Serum uric acid (mg/dL) concentration will be positively associated with
blood pressure and/or HTN.
2. Vitamin D (25(OH)D, nmol/L) levels will be inversely associated with SBP. High serum uric acid
(mg/dL) will attenuate this association; therefore the protective effect of good vitamin D status
on blood pressure and/or HTN will be less significant in subjects who drank more SSBs.
Specific Aim 1: 25(OH)D (nmol/L) concentration will be negatively associated with
elevated systolic blood pressure when assessed with linear and logistic regression, when
adjusted as above.
Specific Aim 2: Serum PTH (pg/mL) concentration will be positively associated with
blood pressure and/or HTN when controlling for 25(OH)D (nmol/L).
Specific Aim 3: Serum UA (mg/dL) will be positively associated with PTH (pg/mL).
Specific Aim 4: Stratified analysis by SSB intake quartile will show that the protective
effect of higher 25(OH)D (nmol/L) concentration on blood pressure and/or HTN is less
significant in subjects in the highest SSB intake quartile.
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CHAPTER 4
METHODS

4.1 Study Population
This study examined participants in the 2003-2004 and 2005-2006 National Health and
Nutrition Survey (NHANES), the only two data releases that include serum PTH measurements.
NHANES collects cross-sectional data from a representative sample of the United States
population of non-institutionalized civilians in order to assess health and lifestyle trends. The
survey is conducted in three phases consisting of a household screener to determine eligibility;
an interview, which includes gathering demographic, health and dietary information, and a
physical examination at which blood and urine samples were collected. The survey subjects
included in this analysis are men and women aged 20-74 who did not report a diagnosis of
hypertension, weak or failing kidneys, diagnosed diabetes or the use of uric-acid-lowering
agents and who completed the physical examination (n=2,875). Previous research on uric acid
suggests that testosterone may play a role in the uric acid formation and that estrogen may
have a protective effect against the development of hyperuricemia (Gao, 2007; Choi, 2008).
Therefore, this study included subgroup analysis by gender and, if any difference between the
genders was found, further subgroup analysis by pre- and post-menopausal women.
Prevalent cases of hypertension, defined as being told by a doctor that you have
elevated blood pressure at least two times or being prescribed antihypertensive medication,
were excluded to prevent medication or other blood pressure lowering therapies from
impacting the outcome variable. Subjects taking allopurinol and other uricosic agents were
excluded for the same reason. Kidney failure impacts the production of 1,25(OH)D; therefore,
subjects who answered yes to the question “Have you ever been told you have weak or failing
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kidneys” were also excluded. The age range for inclusion begins at 20 because data gathered
from the alcohol use questionnaire, an important confounder for HTN, are only included in the
public release for subjects 20 years or above. Subjects over the age of 75 were also excluded,
since increasing age is strongly correlated with HTN. Statistics from the American Heart
Association show that 76.4% of men and 79.9% of women above age 75 have HTN (Mozaffarian,
2015). Age may be such an important predictor of HTN that it has the potential to overwhelm
the impact of other factors, like SSB use and vitamin D status.

4.2 Measurements
Blood pressure was measured during the physical examination at the Mobile
Examination Center. Participants sat quietly for five minutes after which three or four blood
pressure measurements were taken with a calibrated sphygmomanometer (Calibrated® V-Lok®
cuff, Latex Inflation Bulb, Air-Flo® Control Valve, Baumanometer® calibrated mercury true
gravity wall model pressure gauge) by a trained examiner (CDC, 2003). Details on the
examination procedure can be found in the National Health and Nutrition Examination Survey
Physicians Examination Procedures Manuel (CDC, 2003).
Serum 25(OH)D was assessed using the Diasorin (formerly Incstar) (Stillwater, MN) 25hydroxyvitamin D antibody assay. An Elecsys 1010 analyzer (Roche Diagnostics, Indianapolis, IN)
was used to measure serum PTH by electrochemiluminescent immunoassay. Serum uric acid
was measured with a Beckman Synchron LX20 analyzer (Brea, CA). Details on the collection,
storage and analysis procedure can be found in the National Health and Nutrition Examination
Survey Laboratory Procedures Manuel (CDC, 2004).
BMI was calculated as kg/m2 from height and weight measurements taken during the
physical examination. All other covariate data were collected by survey. SSB intake was collected
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by food frequency questionnaire mailed to participants and filled out by them. Examples of all
questionnaires used can be found at https://www.cdc.gov/nchs/nhanes/nhanes20032004/questionnaires03_04.htm.

4.3 Statistical Analysis
All statistical analyses were conducted using STATA/IC version 14.2 statistical software
(STATA Corporation, College Station, TX, USA). Means, standard deviations and ranges were
used to define characteristics of the study population for continuous variables and number and
percent were used for categorical variables. T-tests and chi-square tests were used to determine
if there was a statistically significant difference in means and proportions for covariates
between subjects with elevated (≥120mmHg) or normal (<120mmHg) systolic blood pressure.
All linear and logistic regressions used the same three models. Model 1 controlled for
age and gender. Model 2 also included race/ethnicity and BMI and Model 3 had smoking,
alcohol use, and physical activity added. In addition to these three models, subpopulation
analysis by gender was also performed using Model 3. Both linear and logistic regression were
used to assess the associations between SSB intake and BP, SSB intake and UA, UA and BP,
vitamin D status and BP, PTH and BP, and PTH and UA, using all three models. The regressions
examining PTH with BP and UA were also run controlling for vitamin D status. Education level,
household income, poverty to income ratio, serum vitamin C and waist circumference were all
also evaluated for inclusion in the final models. They were evaluated to see if their univariate
association with SBP had a p-value less than 0.20. If so, the fully adjusted model, Model 3, was
run with and without each of the covariates and those whose addition resulted in a greater than
10% change in the beta coefficients for SBP measurements would have been included in the
final model. None of these additional variables met that standard.
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Blood pressure was assessed both as a continuous variable and also categorically, as
defined above. Subjects whose SBP was more than two standard deviations away from the
mean for the population were excluded from this study (n=164). Vitamin D was categorized by
serum 25(OH)D concentration as less than 50nmol/L, 50-75nmol/L, and greater than 75nmol/L.
SSBs categories were determined by quartiles of intake. Physical activity was categorized by
metabolic activity of task (MET) scores divided into quartiles with a fifth group, the reference
group, being those who reported no leisure time physical activity. Smoking was categorized as
current smokers or non-smokers. Alcohol use was divided by the average number of drinks on
days when alcohol was drunk into categories of non-drinker, one to two drinks, three to four
drinks or five or more. The two continuous variables used were UA and PTH. UA was acceptably
normally distributed, but PTH was skewed, so a log transformed variable of PTH was used in the
regressions. Where PTH was the outcome variable, the anti-log was presented.
In order to answer the question of whether high SSB intake modifies the impact of low
vitamin D levels on blood pressure or vise versa, a possible interaction between SSB and
25(OH)D status on blood pressure or hypertension was investigated by means of linear
regression and logistic regression. Both variables were included in the same model with SBP as
the outcome variable to see if controlling for both modified the associations. Evidence of an
interaction was also investigated using a multiplicative term of SSB intake and vitamin D as
continuous variables. Stratified analyses by vitamin D category and SSB intake quartile were also
conducted using Model 3.
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CHAPTER 5
RESULTS

Table 5.1 shows the unadjusted study population characteristics divided by systolic
blood pressure above or below the elevated range. Those with elevated SBP were older,
heavier, had lower mean serum 25(OH)D but higher UA and PTH, and were more likely to be
men and African American. There was a difference of borderline significance in physical activity
levels and no difference in mean SSB intake, smoking or alcohol use.
Linear and logistic regression models exploring the association between SSB and SBP are
shown in Table 5.2. In linear regression of the total population, SSB intake was positively
associated with blood pressure. In Model 3, there was an increase of 1.40mmHg (95% CI: 0.222.57, p-value 0.02) in the fourth quartile of SSB intake relative to the first, after adjustment for
age, gender, race, BMI, physical activity, alcohol use and smoking. In logistic regression,
increased SSB intake was associated with a significant 40% increase in elevated SBP risk, but this
association was attenuated in the fully adjusted model and was no longer significant. Subgroup
analysis by gender of the fully adjusted model revealed a striking difference between men and
women. Men showed no statistically significant association in any quartile in either linear or
logistic regression. However, in women there was a statistically significant increase of
1.55mmHG (95% CI: 0.05-3.05, p-value 0.042) in the third quartile and 1.78mmHG (95% CI: 0.183.37, p-value 0.029) in the fourth quartile. In logistic regression, risk of elevated SBP was 68%
higher among subjects in the fourth SSB intake quartile compared to those in the first quartile
(OR: 1.68, 95% CI: 1.12-2.50, p-value 0.011).

39

Table 5.1: Subject characteristics by normal versus elevated SBP (n=3,287).
Systolic Blood Pressure
Mean (SD)
Age
BMI
SSB Intake (servings/day)
Serum 25(OH)D (nmol/L)
Serum Uric Acid (mg/dL) (n=2,862)
Serum PTH (pg/mL) (n=2,872)
Count (row %)
Gender
Male
Female
BMI
Normal (Under 25kg/m2)
Overweight (25-29.9kg/m2)
Obese (Over 30 kg/m2)
Race
White
Black
Hispanic
Other
Physical Activity 1
Inactive
MET Quartile 1
MET Quartile 2
MET Quartile 3
MET Quartile 4
Smoking
Current smoker
Non-smoker
Alcohol Use2
Non-drinker
1 to 2 drinks/ day
3-4 drinks/ day
5 or more drinks/day

≤120mmHg
(n=1,875)

>120mmHg
(n=1,000)

p-value

36.6 (12.8)
26.9 (5.5)
1.07 (1.7)
62.8 (23.8)
4.8 (1.3)
38.6 (17.9)

45.4 (14.8)
28.6 (5.5)
1.07 (1.6)
58.2 (22.0)
5.5 (1.3)
44.6 (19.9)

0.000
0.000
0.964
0.000
0.000
0.000

711 (53.7)
1,164 (75.1)

614 (46.3)
386 (24.9)

784 (74.2)
640 (63.1)
451 (56.0)

272 (25.8)
374 (36.9)
354 (34.98)

0.000

0.000

0.016
1,008 (65.2)
311 (60.0)
469 (69.0)
87 (65.9)

537 (34.8)
207 (40.0)
211 (31.0)
45 (34.1)

1,275 (66.7)
145 (60.7)
158 (67.5)
147 (61.3)
150 (60.0)

637 (33.3)
94 (39.3)
76 (32.5)
93 (38.8)
100 (40.0)

0.056

0.778
471 (65.8)
1,404 (65.4)

256 (35.2)
744 (34.6)

441 (68.3)
855 (64.6)
362 (66.4)
217 (60.1)

205 (31.7)
468 (35.4)
183 (33.6)
144 (39.9)

0.062

1 Physical activity: Active=has engaged in moderate or vigorous leisure-time physical activity in
the last 30 days, Inactive=has not engaged in leisure-time physical activity in last 30 days
2 Alcohol Use, n=1,313: Average number of drinks on days when alcohol was consumed
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Table 5.2: Linear and logistic regression analysis of the association of SBP with SSB intake.
SSB Intake
Q1
Servings per day
0-0.08
Whole Population (n=2,875)
Model 1
Reference
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Model 2
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Model 3
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Men (n=1,325)
Model 3
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Women (n=1,550)
Model 3
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value

Q2
0.09-0.42

Q3
0.43-1.28

Q4
1.29-14

1.15 (0.01, 2.28)
0.048
1.30 (1.02, 1.64)
0.031

1.66 (0.51, 2.82)
0.005
1.25 (0.98, 1.59)
0.066

2.31 (1.13, 3.49)
0.000
1.40 (1.09, 1.78)
0.008

0.75 (-0.37, 1.86)
0.188
1.23 (0.97, 1.57)
0.086

1.17 (0.03, 2.30)
0.045
1.18 (0.93, 1.51)
0.178

1.54 (0.37, 2.70)
0.010
1.28 (0.99, 1.64)
0.057

0.73 (-0.38, 1.84)
0.199
1.23 (0.97, 1.56)
0.092

1.06 (-0.08, 2.20)
0.069
1.17 (0.91, 1.50)
0.225

1.40 (0.22, 2.57)
0.020
1.26 (0.98, 1.63)
0.074

1.10 (-0.70, 2.91)
0.231
1.24 (0.87, 1.75)
0.232

0.86 (-0.91, 2.62)
0.340
1.06 (0.76, 1.49)
0.737

0.99 (-0.80, 2.77)
0.277
1.03 (0.73, 1.45)
0.858

0.69 (-0.71, 2.09)
0.336
1.27 (0.90, 1.81)
0.175

1.55 (0.05, 3.05)
0.042
1.39 (0.95, 2.05)
0.088

1.78 (0.18, 3.37)
0.029
1.68 (1.12, 2.50)
0.011

Model 1: Adjusted for age and gender
Model 2: Adjusted for Model 1 plus race and BMI category
Model 3: Adjusted for Model 2 plus leisure time physical activity, smoking status, and alcohol

Further subgroup analysis was performed with women divided into pre- and postmenopausal groups based on self-report of menopause or hysterectomy on the questionnaire
portion of NHANES. No statistically significant association between SSB intake and SBP was
found in post-menopausal women (Table 5.3). However, in pre-menopausal women, the
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Table 5.3: Linear and logistic regression analysis of the association of SBP with SSB intake in
women.
SSB Intake
Q1
Q2
Servings per day
0-0.08
0.09-0.42
Women, controlling for menopause status (n=1,548)
Model 3
Beta (95% CI)
0
0.60 (-0.80, 2.00)
p-value
0.402
OR (95% CI)
1.00
1.27 (0.89, 1.78)
p-value
0.182
Post-menopause (n=374)
Model 3
Beta (95% CI)
-2.08 (-5.05, 0.90)
p-value
0.171
OR (95% CI)
0.73 (0.42, 1.27)
p-value
0.265
Pre-menopause (n=1,174)
Model 3
Beta (95% CI)
0
1.73 (0.15, 3.30)
p-value
0.032
OR (95% CI)
1.00
1.87 (1.17, 2.98)
p-value
0.008

Q3
0.43-1.28

Q4
1.29-14

1.48 (-0.02, 2.98)
0.053
1.39 (0.95, 2.04)
0.090

1.64 (0.05, 3.24)
0.044
1.68 (1.13, 2.51)
0.011

0.05 (-3.61, 3.71)
0.977
1.35 (0.69, 2.65)
0.376

1.34 (-2.67, 5.34)
0.512
1.76 (0.83, 3.73)
0.138

2.02 (0.39, 3.65)
0.015
1.58 (0.96, 2.59)
0.071

2.30 (0.58, 4.02)
0.009
2.05 (1.24, 3.41)
0.005

Model 3: Adjusted for age, gender, race, BMI category, leisure time physical activity, smoking
status, and alcohol

positive association between SSB intake and SBP was much stronger than in women as a whole,
even after controlling for menopause status. In linear regression, pre-menopausal women
showed a statistically significant increase in SBP in all three quartiles relative to the lowest
quartile; 1.73mmHG in quartile 2, 2.02mmHg in quartile 3 and 2.30mmHg in quartile 4. In
quartile 4, pre-menopausal women also showed a statistically significant 105% increase in risk of
elevated SBP (OR: 2.05, 95% CI: 1.24-3.41, p-value 0.005).
Serum UA was found to be associated with SBP, with a 0.83mmHg increase in SBP per
mg/dL increase in UA concentration in the fully adjusted model (Beta: 0.83mmHg, 95% CI: 0.441.21, p-value 0.000). This association is statistically significant but the effect size is very small,
raising doubts about its biological significance. However, logistic regression analysis revealed a
14% increase in risk of elevated SBP in the third model (OR: 1.14, 95% CI: 1.05-1.24, p-value
0.001), which may be clinically relevant. As with the association between SSBs and SBP, the
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analysis is more interesting when separated by gender. No significant association between
serum UA and SBP was observed in men (OR: 0.99, 95% CI: 0.9-1.11, p-value: 0.992), but risk of
elevated SBP was 32% higher per mg/dL increase in UA in women (OR: 1.32, 95% CI: 1.14-1.52,
p-value: 0.000). Pre-menopausal women in particular showed an association, with a 1.35mmHg
increase in SBP and a 47% increased risk of elevated SBP per mg/dL increase in UA (Beta: 1.35,
95% CI 0.73-1.98, p-value 0.000; OR 1.47, 95% CI 1.23-1.76, p-value 0.000), whereas postmenopausal women showed no statistically significant association in linear or logistic regression.
No association was found between SSB intake and serum UA in any intake quartile in any of the
three models, either in the whole study population or in men and women separately.
Vitamin D in the form of 25(OH)D concentration was inversely associated with blood
pressure in the fully-adjusted model (Table 5.4). SBP was 1.74mmHg lower in those with levels
over 75nmol/L compared to those with 50nmol/L or less (Beta: -1.74, 95% CI: -2.87- -0.61, pvalue 0.003). In logistic regression models, the risk of elevated SBP was 30% lower in those in
the highest 25(OH)D category versus those in the lowest category (OR: 0.70, 95% CI: 0.55-0.90,
p-value: 0.005). The relationship between 25(OH)D concentration and SBP was largely
unchanged with subgroup analysis by gender, however, the association was no longer
statistically significant. Further subgroup analysis again revealed that pre-menopausal women
had a much stronger association than post-menopausal women, with a decrease of 1.66mmHg
in the middle 25(OH)D group (Beta: -1.66, 95% CI: -3.12, -0.19, p-value 0.026) and 1.80mmHg in
the highest group relative to the lowest group (Beta: -1.80, 95% CI: -3.41, -0.19, p-value 0.029).
In logistic regression, pre-menopausal women in the highest 25(OH)D group also showed a
borderline significant 38% decrease in risk of elevated SBP (OR: 0.62%, 95% CI: 0.38-1.01, pvalue 0.053).
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Table 5.4: Linear and logistic regression analysis of the association of SBP with
Vitamin D.
25(OH)D (nmol/L)
<50nmol/L
Whole Population (n=2,875)
Model 1
Reference
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Model 2
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Model 3
Beta (95% CI)
0
p-value
OR (95% CI)
1.00
p-value
Men (n=1,325)
Beta (95% CI)
p-value
OR (95% CI)
p-value
Women (n=1,550)
Beta (95% CI)
p-value
OR (95% CI)
p-value

50-75nmol/L

>75nmol/L

-1.95 (-2.89, -1.01)
0.000
0.75 (0.62, 0.91)
0.003

-3.19 (-4.22, -2.16)
0.000
0.58 (0.47, 0.73)
0.000

-0.82 (-1.79, 0.16)
0.100
0.88 (0.71, 1.08)
0.206

-1.66 (-2.79, -0.54)
0.004
0.72 (0.57, 0.93)
0.010

-0.84 (-1.82, 0.14)
0.093
0.86 (0.70, 1.06)
0.166

-1.74 (-2.87, -0.61)
0.003
0.70 (0.55, 0.90)
0.005

-0.21 (-1.65, 1.23)
0.774
0.90 (0.68, 1.19)
0.459

-1.47 (-3.22, 0.30)
0.103
0.77 (0.55, 1.08)
0.127

-1.33 (-2.66, -0.003)
0.049
0.82 (0.60, 1.14)
0.240

-1.52 (-3.00, -0.04)
0.044
0.71 (0.49, 1.03)
0.074

Model 1: Adjusted for Age
Model 2: Adjusted for Model 1 plus Race and BMI category
Model 3: Adjusted for Model 2 plus Leisure time physical activity, smoking status, and alcohol

Examining the relationship between 25(OH)D concentration and SBP with 25(OH)D
dichotomized as deficient or not deficient (below or above 37.5nmol/L) also revealed greater
differences between the genders. The analysis of the total population was within 0.1mmHg of
the results of the linear regression analysis and one percentage point of the results of the
logistic regression analysis above. However, analysis separated by gender revealed no significant
association in men but a 1.64mmHg reduction in SBP (Beta: -1.63, 95% CI: -3.15, -0.11, p-value
0.035) and a 33% reduction in risk of elevated SBP for women who were not vitamin D deficient
compared to those who were deficient (OR: 0.67, 95% CI: 0.47-0.95, p-value 0.025). Post-
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menopausal women showed no association in either linear or logistic regression but nondeficient pre-menopausal women had a 2.47mmHg reduction in SBP compared to those who
were deficient (Beta: -2.47, 95% CI: -4.13, -0.82, p-value 0.003) and a 45% reduction in risk of
elevated SBP (OR 0.55, 95% CI: 0.35-0.85, p-value 0.007).
The association between SBP and PTH, as an index of 1,25(OH)D availability, was also
examined (Table 5.5). SBP, as a continuous variable, was significantly positively associated with

Table 5.5: Linear and logistic regression analysis of the
association of SBP with PTH (pg/mL in linear; elevated PTH
(>65pg/mL) in logistic).
PTH Only
Whole Population (n=2,872)
Model 1
Beta (95% CI)
3.21 (2.29, 4.13)
p-value
0.000
OR (95% CI)
1.95 (1.50, 2.55)
p-value
0.000
Model 2
Beta (95% CI)
2.53 (1.61, 3.46)
p-value
0.000
OR (95% CI)
1.79 (1.37, 2.35)
p-value
0.000
Model 3
Beta (95% CI)
2.58 (1.65, 3.51)
p-value
0.000
OR (95% CI)
1.70 (1.30-2.23)
p-value
0.000
Men (n=1,323)
Model 3
Beta (95% CI)
3.20 (1.71, 4.68)
p-value
0.000
OR (95% CI)
1.83 (1.25-2.70)
p-value
0.002
Women (n=1,549)
Model 3
Beta (95% CI)
1.83 (0.63, 3.03)
p-value
0.003
OR (95% CI)
1.50 (1.00-2.25)
p-value
0.050

Controlling for 25(OH)D

2.59 (1.63, 3.55)
0.000
1.79 (1.37, 2.35)
0.000
2.35 (1.40, 3.29)
0.000
176 (1.32, 2.28)
0.000
2.37 (1.40, 3.33)
0.000
1.64 (1.25-2.16)
0.000

3.08 (1.57, 4.60)
0.000
1.79 (1.22-2.65)
0.003

1.61 (0.36, 2.85)
0.012
1.43 (0.95-1.18)
0.090

Model 1: Adjusted for Age and gender
Model 2: Adjusted for Model 1 plus Race and BMI category
Model 3: Adjusted for Model 2 plus Leisure time physical activity, smoking status, and alcohol
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PTH, which remained largely unchanged in all models with and without controlling for 25(OH)D
concentration. For each additional pg/mL of serum PTH, subjects showed a 2.37mmHg higher
SBP in the fully adjusted model in the linear regression (Beta: 2.37mmHg, 95% CI: 1.40-3.33, pvalue 0.000). In logistic regression, the risk of elevated SBP of was 64% higher in subjects with
elevated serum PTH (OR: 1.64, 95% CI: 1.25-2.16, p-value 0.000 for fully adjusted model). The
findings were markedly different in men and women. When SBP was examined as a continuous
variable, men showed a 3.08mmHg increase in SBP per pg/mL increase in PTH (Beta: 3.08mmHg,
95% CI: 1.57-4.60, p-value 0.000), while women only had a 1.61mmHg increase (Beta: 1.61, 95%
CI: 0.36-2.85, p-value 0.012). In logistic regression, men with elevated PTH had a statistically
significant 79% increased risk of elevated SBP (OR: 1.79, 95% CI: 1.22-2.65, p-value 0.003) and
women with elevated PTH had a much smaller and non-significant 43% increase in risk (OR:
1.43, 95% CI 0.95-1.18, p-value 0.090 for women). In logistic regression, post-menopausal
women showed no statistically significant association between PTH and SBP, but premenopausal women with elevated PTH showed an 83% increased risk of elevated SBP (OR: 1.83,
95% CI: 1.09-3.09, p-value 0.023.)
To investigate the hypothesis that high UA concentration would lead to decreased
1,25(OH)D production and subsequently lead to a buildup of PTH, the association between PTH
and UA was also examined. Each mg/dL increase in UA was associated with a statistically
significant increase of 1.05pg/mL of PTH (Beta: 1.05, 95% CI: 1.04-1.07, p-value 0.000 in fully
adjusted model). This corresponds with a 23% increased risk of elevated PTH (>65pg/mL) in the
fully adjusted model controlled for 25(OH)D concentration (OR: 1.23, 95% CI: 1.09-1.38, p-value
0.001). There was very little difference between men and women in subgroup analysis by
gender.

46

Including both SSB intake and 25(OH)D status in the same model did not substantially
modify either association with SBP or risk of elevated SBP in the fully adjusted model (Table 5.6),
which held true for subgroup analysis by gender. Including a multiplicative term to assess
interaction between vitamin D and SSB intake did not result in a statistically significant
association or modification of the main effects. Stratified analysis by SSB intake quartile
revealed no statistically significant associations between 25(OH)D concentration and SBP.

Table 5.6: Linear and logistic regression analysis of the association of SBP with SSB intake and
Vitamin D.
Whole Population (n=2,875)
SSB Intake
Model 3
Beta (95% CI)
p-value
OR (95% CI)
p-value
Vitamin D
Model 3
Beta (95% CI)
p-value
OR (95% CI)
p-value

Q1
0.00
1.00
<50nmol/L
0.00
1.00

Q2

Q3

0.70 (-0.41, 1.82)
0.214
1.22 (0.96, 1.56)
0.103
50-75nmol/L

1.01 (-0.13, 2.15)
0.083
1.16 (0.90, 1.48)
0.251
>75nmol/L

-0.79 (-1.77, 0.19)
0.116
0.87 (0.71, 1.07)
0.191

-1.66 (-2.79, -0.53)
0.004
0.71 (0.56, 0.91)
0.007

Q4
1.28 (0.10, 2.46)
0.034
1.23 (0.96, 1.59)
0.107

Model 3: Adjusted for age, gender, race, BMI category, leisure time physical activity, smoking
status, and alcohol

Analyzing the data stratified by Vitamin D status, there was a statistically significant finding in
one group; for subjects with 25(OH)D concentrations below 50nmol/L, being in the highest SSB
intake quartile resulted in a 66% increase in risk of HTN (OR: 1.66, 95% CI: 1.05-2.61, p-value
0.029). All interaction and stratified models were adjusted for age, gender, race, BMI category,
leisure time physical activity, smoking status, and alcohol.
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CHAPTER 6
DISCUSSION

6.1 Sugar-sweetened Beverages and Hypertension
We found a positive association between SSB intake (in quartiles) and systolic blood
pressure, whether blood pressure was modeled as a continuous or a categorical variable. This
observation is consistent with previous research on SSB intake in adults (Barrio-Lopez, 2013;
Cohen, 2012; Ejtahed, 2015; Jayalath,2015; Sayon-Orea, 2015). For the continuous analysis, this
association was statistically significant only in the fourth quartile for the fully adjusted model,
with an increase in SBP of 1.40mmHg relative to the lowest intake quartile. In logistic regression,
the risk of elevated SBP was also 26% higher in the fourth quartile, but this association was not
statistically significant. Earlier studies reported associations of a similar magnitude: a 1.8mmHg
increase in SBP (Ejtahed, 2015) and ORs for HTN of 1.27 (Ejtahed, 2015), 1.13 (Cohen, 2012) and
1.12 (Jayalath,2015).
Subgroup analysis by gender revealed no statistically significant association in men
between SSB intake and increased SBP in any quartile. Among women, on the other hand, a
statistically significant association was observed in both the third (1.55mmHg increase) and
fourth (1.78mmHG increase) SSB quartiles in the continuous SBP analysis, as well as a 68%
increase in risk of elevated SBP in the 4th quartile in the logistic analysis. This difference between
genders was observed in some earlier studies as well. Cohen et al found a statistically significant
association between SSB intake and HTN in their analysis of the Nurses’ Health Study (HR: 1.12,
95% CI: 1.08–1.17) and Nurses’ Health Study II (HR: 1.17, 95% CI: 1.11–1.23) participants, which
are female cohorts, but not in Health Professionals Study (HR: 1.06, 95% CI: 0.99–1.14)
participants, which is a male cohort (Cohen, 2012). Sayon-Orea also found a stronger,
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statistically significant association in women but none in men (women: HR: 1.55, 95% CI: 1.11–
2.15, men: HR: 1.20, 95% CI: 0.91–1.57) (Sayon-Orea, 2015). These findings indicate that the
association between SSBs and SBP depends on gender and that high SSB intake may only be a
risk factor for elevated SBP in women. To elucidate a possible cause for that difference, further
subgroup analysis was performed on women divided into pre- and post-menopausal groups.
That analysis showed no statistically significant association between SSB intake and SBP in postmenopausal women, but in pre-menopausal women showed a 2.30mmHg increase in SBP in
quartile 4 in linear regression as well as a statistically significant 105% increase in risk of
elevated SBP in logistic regression. This sharp difference between pre- and post-menopausal
women in the impact of SSB intake on SBP suggests that estrogen may have a mechanistic role
in that relationship, since a drop in estrogen levels is one of the primary changes of menopause.
Our study confirms earlier reports of an association between serum UA and BP or HTN
(Alper, 2005; Bobridge, 2013; Nguyen, 2009; Sundstrom, 2005). In the fully adjusted linear
regression model, each mg/dL increase in UA concentration was associated with a statistically
significant 0.83mmHg increase in SBP and a 14% increase in risk of elevated SBP per mg/dL
increase in UA was found in logistic regression. Alper and colleagues (2005) previously found
that the association was stronger in men than in women, and we also found a similar result in
our study. No significant association between serum UA and SBP was observed in men but in
women the risk of elevated SBP was 32% higher per mg/dL increase in UA. Pre-menopausal
women showed a 1.35mmHg increase in SBP and a 47% increased risk of elevated SBP per
mg/dL increase in UA while no relationship was found in post-menopausal women. As with the
analysis of SSB and SBP, the difference in findings between men and women and pre- and postmenopausal women suggests a possible role for estrogen in the mechanism linking UA and SBP.
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The similar pattern of the association between SSB intake with SBP and UA with SBP,
with an association found in women but not men and the strongest association in premenopausal women, seemed promising for the hypothesis that increased UA was integral to the
relationship between SSBs and SBP. Increased uric acid production has been widely proposed as
a possible mechanistic link between SSB intake and increased BP (Brown, 2011; Ejtahed, 2015;
Jayalath, 2015; Kim, 2012; Nguyen, 2009), and some earlier studies that examined the impact of
SSB intake on serum UA concentration did find a statistically significant association, although the
effect size was very small (Choi, 2008; Gao, 2007). However, we found no association between
SSB intake and serum UA in any quartile. No association was observed in either gender in
subgroup analysis, despite earlier studies suggesting that men were most likely to form UA in
response to SSB intake (Choi, 2008; Gao, 2007). Additional metabolic studies may be needed to
determine the mechanism underlying the gender differences observed in earlier studies of SSBs
and UA. Finding no association between SSBs and UA also leaves unanswered the question of
mechanisms in the associations we observed in pre-menopausal women between SSBs and SBP
and UA and SBP in other parts of this study.

6.2 Vitamin D and Hypertension
We found a negative association between 25(OH)D status and blood pressure. In
adjusted linear regression, being in the highest 25(OH)D category was associated with a
1.74mmHg decrease in SBP relative to the lowest category. In addition, a 30% reduction in risk
of elevated SBP was observed in subjects with serum 25(OH)D concentrations greater than
75nmol/L compared to those with under 50nmol/L. This finding is generally consistent with a
2011 meta-analysis that found a 27% decrease in risk of HTN in subjects with the highest
25(OH)D levels (Burgaz, 2011). When we analyzed by gender, the relationship between vitamin
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D and SBP was similar but was no longer statistically significant, perhaps as the result of the
smaller sample size. That would suggest that gender does not play a role in the relationship
between 25(OH)D and SBP. However, further subgroup analysis again revealed that premenopausal women had a much stronger association than post-menopausal women, with a
1.80mmHg decrease in SBP and a borderline significant 38% decrease in risk of elevated SBP in
the highest group relative to the lowest. Analysis with 25(OH)D as a dichotomous variable
(deficient or not deficient) resulted in larger differences between the genders. Here there was
no significant association in men but a 1.64mmHg reduction in SBP and a 33% reduction in risk
of elevated SBP for women who were not vitamin D deficient compared to those who were
deficient. Further subgroup analysis for women revealed that post-menopausal women had no
association in either linear or logistic regression but non-deficient pre-menopausal women had a
2.47mmHg reduction in SBP compared to those who were deficient and a 45% reduction in risk
of elevated SBP. As with the analysis looking at the impact of SSBs and UA on SBP, the difference
between pre-menopausal women and men or post-menopausal women suggests that estrogen
may be involved in the relationship between 25(OH)D and SBP.
Serum PTH has been proposed as an index of the body’s ability to convert 25(OH)D to
1,25(OH)D (Chen, 2014). As such, the possibility of an association between serum PTH and SBP
was examined to determine if inability to activate vitamin D was more important to BP
outcomes than simply the availability of sufficient precursor in the form of 25(OH)D. A
statistically significant positive association was found between PTH and SBP. For each additional
pg/mL of serum PTH, subjects showed a 2.37mmHg higher SBP in the fully adjusted model in the
linear regression and in logistic regression the risk of elevated SBP was 64% higher in subjects
with elevated serum PTH.
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The findings were markedly different in men and women, but in this case the
association was nearly twice as strong in men in both linear and logistic regression. In logistic
regression, post-menopausal women showed no statistically significant association between
PTH and SBP, but pre-menopausal women with elevated PTH showed an 83% increased risk of
elevated SBP. Finding a similar relationship between pre-menopausal women relative to postmenopausal women and between men relative to women suggests that the sex hormone
impacting the association between PTH and SBP may be testosterone, rather than estrogen.
Testosterone levels drop in women after menopause; so men and pre-menopausal women are
similar in that they have higher testosterone levels whereas men and post-menopausal women
are similar in that they have lower estrogen levels. While the relationships between SBP and
SSBs, 25(OH)D and PTH all appear to be impacted by sex hormones, the specific androgen
involved may be different.
Serum UA was positively associated with PTH, with a statistically significant increase of
1.05pg/mL of PTH per mg/dL increase in UA and a 23% increased risk of elevated PTH
(>65pg/mL) in the fully adjusted model controlled for 25(OH)D concentration. These findings are
consistent with earlier studies of UA and PTH, many of which used the same 2003-2006 NHANES
data, as these are the only years for which PTH data are available (Alemzadeh, 2016; Chen,
2014; Chin, 2015; Hernández, 2015; Hsu, 1991; Hui, 2012; Paik, 2012). Controlling for 25(OH)D
did not substantially modify the relationship in any of the models. These findings suggest that
UA may play a role in the elevation of PTH and therefore SBP. However, the fact that the
association between UA and SBP was found to be more significant in women and the association
between PTH and SBP was found to be more significant in men raises doubts about connecting
the two pathways.
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6.3 Interaction Between SSB Intake and Vitamin D
One of the main objectives of this study was to assess possible effect modification by
vitamin D of the relationship between SSB intake and HTN. Evidence supporting the proposed
mechanism for that interaction—high SSB intake increases serum UA, which decreases 25(OH)
D activation to 1,25(OH)D as indexed by serum PTH—was not found in the study population,
with no association observed between SSB intake and UA. The study has also found no evidence
of effect modification. Including both SSB intake and 25(OH)D status in regression models did
not substantially modify either association with SBP or risk of elevated SBP in the fully adjusted
model, either in the whole population or in subgroup analysis by gender. Using a multiplicative
term of 25(OH)D and SSB intake also did not produce a statistically significant result or modify
either individual association to a meaningful degree. Stratified analysis both by SSB intake
quartile also provided no evidence of an interaction.
Stratification by 25(OH)D status showed an interaction between vitamin D and SSB
intake in subjects in the highest SSB intake quartile. For subjects with 25(OH)D concentrations
below 50nmol/L, being in the highest SSB intake quartile was associated with a borderlinesignificant 2.04mmHg increase in SBP and a statistically significant 66% increase in risk of
elevated SBP. While these findings provide some evidence of effect modification, a
multiplicative interaction term inserted into the final model was not significant. We suggest that
the increased risk of elevated SBP in people who have both low 25(OH)D status and high SSB
intake is simply the result of having two risk factors for high SBP, but that there is no evidence
that the effect is more than additive.
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6.4 Limitations
In assessing the relationship between SSB intake and serum UA, an attempt was made
to understand the impact of difference in testosterone and estrogen levels by using subgroup
analysis by gender and between pre- and post-menopausal women. Although controlling for
these variables directly in our analysis may have been more informative, testosterone and
estradiol were only measured in a subset of men during the 2003-2004 NHANES survey. After
excluding subjects who did not complete the food frequency questionnaire, only a very small
sample (n=134) remained, so these data were not analyzed as part of the current study.
Another limitation in the assessment of the association between UA and SBP was the
cross-sectional nature of the study. Some earlier animal research suggested that the impact of
UA on HTN may be delayed; structural changes to the kidneys caused by UA may not increase BP
immediately but will result in HTN in the presence of a high-sodium diet in the future
(Watanabe, 2002). If that is the case, a cross-sectional study is less likely to find an association
between UA and HTN since UA levels may not remain high at the time elevated BP is detected.

6.5 Future Directions
The findings of this study do not provide evidence of an interaction between SSBs or
25(OH)D and SBP. Therefore, future studies examining the effect of SSB intake on BP will not
need to include PTH, whose inclusion in our study limited our available sample size to years for
which PTH measurements were available. Removing these requirements opens up the
possibility of conducting a much larger study of this effect while still using NHANES data. The
FFQ was used only in 2003-2006, so including data from other years would involve calculating
SSB intake from the 24-hour recall data. This would be more time consuming and complicated
but would have the added benefit of allowing for the inclusion in the model of other dietary
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factors which were not included in the FFQ, such as sodium intake. If the effect remained
significant in cross-sectional analysis of a larger population, more complex study designs, such as
cohort studies, could be used to further investigate the connection. Such studies have been
conducted in the past, but few have directly investigated the mechanism involved. The most
unexpected finding of this study was a null finding; no association was found between SSB
intake and serum UA. Further studies will be needed to firmly conclude that uric acid is not the
mechanism by which high SSB intake increases BP, and ideally these studies will include
measurements of testosterone and estrogen. Other possible mechanisms could also be
investigated, such as insulin resistance. Cross-sectional and cohort study data could also be used
to investigate this possibility, if fasting insulin and glucose level data were available.

6.6 Conclusion
Consistent with earlier studies, we found that SSB intake was positively associated with
SBP and 25(OH)D concentration was negatively associated with SBP. For pre-menopausal
women, reducing the number of SSBs consumed may have a beneficial SBP-lowering effect, and
both men and women may benefit from having a higher serum 25(OH)D concentrations. We did
not find an association between SSB intake and UA or evidence of an interaction between SSBs
and vitamin D in their impact on SBP. Further studies will be needed to elucidate the
mechanisms by which low serum 25(OH)D concentration and high SSB intake increase SBP.
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